{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import bert\n",
    "import numpy as np\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import matplotlib.pyplot as plt\n",
    "import spike_queries\n",
    "from termcolor import colored\n",
    "import random\n",
    "from collections import Counter, defaultdict\n",
    "from viterbi_trellis import ViterbiTrellis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "class color:\n",
    "   PURPLE = '\\033[95m'\n",
    "   CYAN = '\\033[96m'\n",
    "   DARKCYAN = '\\033[36m'\n",
    "   BLUE = '\\033[94m'\n",
    "   GREEN = '\\033[92m'\n",
    "   YELLOW = '\\033[93m'\n",
    "   RED = '\\033[91m'\n",
    "   BOLD = '\\033[1m'\n",
    "   UNDERLINE = '\\033[4m'\n",
    "   END = '\\033[0m'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_results(fname):\n",
    "    \n",
    "    with open(fname, \"r\", encoding = \"utf-8\") as f:\n",
    "        sents = f.readlines()\n",
    "    \n",
    "    sents = [s.strip().replace(\"<s1>\",\"\").replace(\"<s2>\",\"\").replace(\"<e1>\", \"\").replace(\"<e2>\",\"\").replace(\"h:\",\"\").\n",
    "             split(\"\\t\")[-1] for s in sents]\n",
    "    original, results = sents[0], sents[1:]\n",
    "    return original, results\n",
    "\n",
    "\n",
    "def get_spike_results_arguments_representations(model, spike_results, layers):\n",
    "    \n",
    "    sents = spike_results[\"sentence_text\"].tolist()\n",
    "    arg1_idx_start = spike_results[\"arg1_first_index\"].to_numpy().astype(int)\n",
    "    arg2_idx_start = spike_results[\"arg2_first_index\"].to_numpy().astype(int)\n",
    "    arg1_idx_end = spike_results[\"arg1_last_index\"].to_numpy().astype(int)\n",
    "    arg2_idx_end = spike_results[\"arg2_last_index\"].to_numpy().astype(int)\n",
    "    \n",
    "    arg1_rep = []\n",
    "    arg2_rep = []\n",
    "    \n",
    "    for s, arg1_start, arg2_start, arg1_end, arg2_end in zip(sents, arg1_idx_start, arg2_idx_start, arg1_idx_end, arg2_idx_end):\n",
    "        #idx_to_mask = [arg1_start, arg2_start, arg1_end, arg2_end]\n",
    "        H, _, _, orig2tok = model.encode(s, layers = layers)\n",
    "\n",
    "        h1, h2 = H[orig2tok[arg1_start]:orig2tok[arg1_end] + 1], H[orig2tok[arg2_start]:orig2tok[arg2_end] + 1]\n",
    "        \n",
    "        h1 = np.mean(h1, axis = 0)\n",
    "        h2 = np.mean(h2, axis = 0)\n",
    "        \n",
    "        arg1_rep.append(h1)\n",
    "        arg2_rep.append(h2)\n",
    "        \n",
    "    arg1_mean = np.mean(arg1_rep, axis = 0)\n",
    "    arg2_mean = np.mean(arg2_rep, axis = 0)\n",
    "        \n",
    "    return arg1_mean, arg2_mean\n",
    "    \n",
    "\n",
    "def print_sentence_nicely(sentence: str, ind1, ind2):\n",
    "    \n",
    "    arg1_sign = \"**\"\n",
    "    arg2_sign = \"++\"\n",
    "    arg1_color, arg2_color = \"red\", \"blue\"\n",
    "    \n",
    "    if not ind2 > ind1: \n",
    "        ind1, ind2 = ind2, ind1\n",
    "        arg1_sign, arg2_sign = arg2_sign, arg1_sign\n",
    "        arg1_color, arg2_color = arg2_color, arg1_color\n",
    "        \n",
    "    splitted = sentence.split(\" \")\n",
    "    before_arg1 = \" \".join(splitted[:ind1])\n",
    "    arg1 = splitted[ind1]\n",
    "    arg2 = splitted[ind2]\n",
    "    between = \" \".join(splitted[ind1 + 1: ind2])\n",
    "    suffix = \" \".join(splitted[ind2+1:])\n",
    "    \n",
    "    return before_arg1 +  \" \" + arg1_sign + colored(arg1, arg1_color) + arg1_sign + \" \" + between + \" \" + arg2_sign + colored(arg2, arg2_color) + arg2_sign + \" \" + suffix\n",
    "\n",
    "\n",
    "\n",
    "def main(filename, layers = [-1], num_results_to_print = 75):\n",
    "    \n",
    "    \n",
    "    query, results1 = load_results(filename)\n",
    "    spike_results = spike_queries.perform_query(query, dataset_name = \"covid19\", num_results = 100, query_type = \"syntactic\")\n",
    "    spike_results = spike_results[spike_results['sentence_text'].notnull()]\n",
    "    arg1_rep, arg2_rep = get_spike_results_arguments_representations(model, spike_results, layers)\n",
    "    \n",
    "    #print(color.BOLD + \"QUERY\" + color.END + \":\\n{}\".format(query))\n",
    "    \n",
    "    first, first_ind1, first_ind2 = spike_results[\"sentence_text\"].tolist()[-1], int(spike_results[\"arg1_first_index\"].tolist()[-1]), int(spike_results[\"arg2_first_index\"].tolist()[-1])\n",
    "    #print(color.BOLD + \"\\nFIRST SPIKE RESULT\" + color.END + \":\\n{}\".format(print_sentence_nicely(first, first_ind1, first_ind2)))\n",
    "    #print(color.BOLD + \"\\nAUGMENTATION RESULTS:\\n\" + color.END)\n",
    "    \n",
    "    representations = []\n",
    "    mappings_to_orig = []\n",
    "    mappings_to_tok = []\n",
    "    tokenized_txts = []\n",
    "    orig_sents = []\n",
    "    \n",
    "    for i,s in enumerate(results1):\n",
    "        H, tokenized_text, tok_to_orig_map, orig2tok = model.encode(s, layers = layers)\n",
    "        orig_sents.append(s)\n",
    "        representations.append(H)\n",
    "        mappings_to_orig.append(tok_to_orig_map)\n",
    "        mappings_to_tok.append(orig2tok) \n",
    "        tokenized_txts.append(tokenized_text)\n",
    "        \n",
    "        if i > num_results_to_print: break\n",
    "    \n",
    "    return query, (arg1_rep, arg2_rep), (representations, mappings_to_orig, mappings_to_tok, tokenized_txts, orig_sents)\n",
    "\n",
    "\n",
    "def get_between_tokens_similarity(padded_representations):\n",
    "    \n",
    "    num_sents, seq_len, bert_dim = padded_representations.shape\n",
    "    padded_representations = padded_representations.reshape((num_sents*seq_len, bert_dim))\n",
    "    sims = cosine_similarity(padded_representations, padded_representations)\n",
    "    sims = sims.reshape((num_sents, seq_len, num_sents, seq_len))\n",
    "    \n",
    "    return sims\n",
    "\n",
    "def get_between_token_similarity_prev_sentence(padded_representations):\n",
    "    \n",
    "    num_sents, seq_len, bert_dim = padded_representations.shape\n",
    "    padded_representations = padded_representations.reshape((num_sents*seq_len, bert_dim))    \n",
    "    padded_representations /= np.linalg.norm(padded_representations, keepdims = True, axis=1)\n",
    "    padded_representations = padded_representations.reshape((num_sents, seq_len, bert_dim))\n",
    "    tuples = list(zip(padded_representations, padded_representations[1:]))\n",
    "    sims = np.array([tup[0].dot(tup[1].T) for tup in tuples])\n",
    "    sims = sims.reshape(((num_sents-1)*seq_len, seq_len))\n",
    "    return sims\n",
    "\n",
    "def get_similarity_to_arguments(padded_representations, arg1, arg2):\n",
    "    num_sents, seq_len, bert_dim = padded_representations.shape\n",
    "    padded_representations = padded_representations.reshape((num_sents*seq_len, bert_dim))\n",
    "    #print(padded_representations.shape)\n",
    "    sims = cosine_similarity([arg1_rep, arg2_rep], padded_representations)\n",
    "    sims = sims.reshape((2, num_sents, seq_len))\n",
    "    return sims"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "loading configuration file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/config.json from cache at /home/shauli/.cache/torch/transformers/199e28e62d2210c23d63625bd9eecc20cf72a156b29e2a540d4933af4f50bda1.4b6b9f5d813f7395e7ea533039e02deb1723d8fd9d8ba655391a01a69ad6223d\n",
      "Model config BertConfig {\n",
      "  \"attention_probs_dropout_prob\": 0.1,\n",
      "  \"hidden_act\": \"gelu\",\n",
      "  \"hidden_dropout_prob\": 0.1,\n",
      "  \"hidden_size\": 768,\n",
      "  \"initializer_range\": 0.02,\n",
      "  \"intermediate_size\": 3072,\n",
      "  \"layer_norm_eps\": 1e-12,\n",
      "  \"max_position_embeddings\": 512,\n",
      "  \"model_type\": \"bert\",\n",
      "  \"num_attention_heads\": 12,\n",
      "  \"num_hidden_layers\": 12,\n",
      "  \"output_hidden_states\": true,\n",
      "  \"pad_token_id\": 0,\n",
      "  \"type_vocab_size\": 2,\n",
      "  \"vocab_size\": 31090\n",
      "}\n",
      "\n",
      "loading configuration file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/config.json from cache at /home/shauli/.cache/torch/transformers/199e28e62d2210c23d63625bd9eecc20cf72a156b29e2a540d4933af4f50bda1.4b6b9f5d813f7395e7ea533039e02deb1723d8fd9d8ba655391a01a69ad6223d\n",
      "Model config BertConfig {\n",
      "  \"attention_probs_dropout_prob\": 0.1,\n",
      "  \"hidden_act\": \"gelu\",\n",
      "  \"hidden_dropout_prob\": 0.1,\n",
      "  \"hidden_size\": 768,\n",
      "  \"initializer_range\": 0.02,\n",
      "  \"intermediate_size\": 3072,\n",
      "  \"layer_norm_eps\": 1e-12,\n",
      "  \"max_position_embeddings\": 512,\n",
      "  \"model_type\": \"bert\",\n",
      "  \"num_attention_heads\": 12,\n",
      "  \"num_hidden_layers\": 12,\n",
      "  \"pad_token_id\": 0,\n",
      "  \"type_vocab_size\": 2,\n",
      "  \"vocab_size\": 31090\n",
      "}\n",
      "\n",
      "Model name 'allenai/scibert_scivocab_uncased' not found in model shortcut name list (bert-base-uncased, bert-large-uncased, bert-base-cased, bert-large-cased, bert-base-multilingual-uncased, bert-base-multilingual-cased, bert-base-chinese, bert-base-german-cased, bert-large-uncased-whole-word-masking, bert-large-cased-whole-word-masking, bert-large-uncased-whole-word-masking-finetuned-squad, bert-large-cased-whole-word-masking-finetuned-squad, bert-base-cased-finetuned-mrpc, bert-base-german-dbmdz-cased, bert-base-german-dbmdz-uncased, bert-base-finnish-cased-v1, bert-base-finnish-uncased-v1, bert-base-dutch-cased). Assuming 'allenai/scibert_scivocab_uncased' is a path, a model identifier, or url to a directory containing tokenizer files.\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/vocab.txt from cache at /home/shauli/.cache/torch/transformers/e3debd8fbdf40874753724814ee0520f612b577b26c8755bca485103b47cd3bc.60287becc5ab96d85a4bf377eb90feaf3b9c80d3b23e84311dccd3588f56d4fb\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/added_tokens.json from cache at None\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/special_tokens_map.json from cache at None\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/tokenizer_config.json from cache at None\n",
      "loading weights file https://cdn.huggingface.co/allenai/scibert_scivocab_uncased/pytorch_model.bin from cache at /home/shauli/.cache/torch/transformers/54e18c298451d3195ba8359e7a3fa2bc04c70c730c5b6744928278e67940eacb.7587182ea55c40bf7fd0961c1176c31fa22558da2bf20c199874fa5a8ecb4613\n"
     ]
    }
   ],
   "source": [
    "model = bert.BertEncoder(\"cuda\", \"scibert\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def get_probable_alignments(sims_args, mappings_to_orig):\n",
    "    argument2sent2alignments = dict()\n",
    "    \n",
    "    \"\"\"\n",
    "    :param sims_args: similarity to arguments per query, shape: [2,num_sents,padded_sent_len]\n",
    "    :return: \n",
    "    \"\"\"\n",
    "    \n",
    "    for arg in range(2):\n",
    "        sent2alignments = dict()\n",
    "        for sent_ind in range(sims_args.shape[1]):\n",
    "            sorted_sims_idx = np.argsort(-sims_args[arg][sent_ind])\n",
    "            sorted_sims_vals = sims_args[arg][sent_ind][sorted_sims_idx]            \n",
    "            sorted_sims_idx_mapped = [mappings_to_orig[sent_ind][j] if j in mappings_to_orig[sent_ind] else -1 for j in sorted_sims_idx]\n",
    "            sent2alignments[sent_ind] = list(zip(sorted_sims_idx_mapped, sorted_sims_vals))\n",
    "        \n",
    "        argument2sent2alignments[arg] = sent2alignments\n",
    "\n",
    "    return argument2sent2alignments"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "nan"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.nan"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "query2arg2preds = defaultdict(dict)\n",
    "\n",
    "for q in [1,2,4,5,6,7,8,9]:\n",
    "    \n",
    "    # collect representations of arguments & results\n",
    "    \n",
    "    fname = \"results{}.txt\".format(q)\n",
    "    query, (arg1_rep, arg2_rep), (representations, mappings_to_orig, mappings_to_tok, tokenized_txts, orig_sents)  = main(fname, layers = [-1])\n",
    "    for i in range(len(representations)): # zero cls, ., sep\n",
    "        representations[i][0][:] = np.random.rand()\n",
    "        representations[i][-1][:] = np.random.rand()\n",
    "        representations[i][-2][:] = np.random.rand()\n",
    "\n",
    "    \n",
    "    pad_width = max([len(s) for s in representations])\n",
    "    padded_representations = np.array([np.concatenate([r, -np.ones((pad_width-len(r), 768))]) for r in representations])\n",
    "\n",
    "    num_sents, seq_len, bert_dim = padded_representations.shape\n",
    "    num_tokens = num_sents * seq_len\n",
    "    sims_args = get_similarity_to_arguments(padded_representations, arg1_rep, arg2_rep) #(2, num_sents, padded_sent_len)\n",
    "    \n",
    "    arguments2sent2alignments = get_probable_alignments(sims_args, mappings_to_orig)\n",
    "    for arg in range(2):\n",
    "        dicts = [{\"sent\": orig_sents[i], \"pred_idx\": list(zip(*arguments2sent2alignments[arg][i]))[0], \n",
    "                \"preds_sims\":  list(zip(*arguments2sent2alignments[arg][i]))[1]} for i in range(num_sents)]\n",
    "        \n",
    "        \n",
    "        query2arg2preds[q][arg] = dicts"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Evalation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_gold():\n",
    "    query2sent2gold = defaultdict(dict)\n",
    "    \n",
    "    for query in [1,2,4,5,6,7,8,9]:\n",
    "        \n",
    "        fname = \"results{}.txt\".format(query)\n",
    "        \n",
    "        with open(fname, \"r\", encoding = \"utf-8\") as f:\n",
    "            sents = f.readlines()\n",
    "    \n",
    "        original, results = sents[0], sents[1:]\n",
    "        \n",
    "        sent2gold = defaultdict(dict)\n",
    "        query_stop = False\n",
    "        \n",
    "        for i,line in enumerate(results):\n",
    "            \n",
    "            if line.count(\"<s1>\") != line.count(\"<e1>\"):\n",
    "                print(line)\n",
    "                print(\"<<<<<ERROR>>>>>\", query, i)\n",
    "            if query_stop: break\n",
    "                \n",
    "            sent_data_relevant = []\n",
    "            sent_data_arg1 = []\n",
    "            sent_data_arg2 = []\n",
    "            \n",
    "            _, sent = line.strip().split(\"\\t\")\n",
    "            tokens = sent.split(\" \")\n",
    "            \n",
    "            found_start_arg1 = False\n",
    "            found_start_arg2 = False\n",
    "            start_arg1 = None\n",
    "            start_arg2 = None\n",
    "            \n",
    "            for j,tok in enumerate(tokens):\n",
    "                \n",
    "                if \"h:\" in tok:\n",
    "                    sent_data_relevant.append(j)\n",
    "                \n",
    "                if \"<s1>\" in tok:\n",
    "                    found_start_arg1 = True\n",
    "                    start_arg1 = j\n",
    "                elif \"<s2>\" in tok:\n",
    "                    found_start_arg2 = True\n",
    "                    start_arg2 = j\n",
    "                \n",
    "                if found_start_arg1 and \"<e1>\" in tok:\n",
    "                    \n",
    "                    sent_data_arg1.append((start_arg1, j))\n",
    "                    \n",
    "                    found_start_arg1 = False\n",
    "                    start_arg1 = None\n",
    "                    \n",
    "                if found_start_arg2 and \"<e2>\" in tok:\n",
    "                    \n",
    "                    sent_data_arg2.append((start_arg2, j))\n",
    "                    \n",
    "                    found_start_arg2 = False\n",
    "                    start_arg2 = None  \n",
    "            \n",
    "            sent2gold[i] = {\"arg1\": sent_data_arg1, \"arg2\": sent_data_arg2, \"relevant\": sent_data_relevant}\n",
    "                \n",
    "            if \"<s1>\" not in sent: \n",
    "                query_stop = True\n",
    "        \n",
    "        query2sent2gold[query] = sent2gold\n",
    "    return query2sent2gold\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RESULT: \u001b[1m[\u001b[94mARG1 Hepatotropic virus ]\u001b[0m , like \u001b[1m[\u001b[94mARG1 MHV-3 infection ]\u001b[0m in mice , can induce \u001b[1m[\u001b[94mARG2 exaggerated inflammation in the liver ]\u001b[0m and cause life-threatening viral FH .\n",
      "ARG1 PREDS: \u001b[94m[p]virus\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mmice\u001b[0m, \u001b[91minflammation\u001b[0m, \u001b[91mcause\u001b[0m, \u001b[92m[c]Hepatotropic\u001b[0m, \u001b[91minduce\u001b[0m, \u001b[91mliver\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]inflammation\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[94m[p]liver\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mmice\u001b[0m, \u001b[91minduce\u001b[0m, \u001b[91mlife-threatening\u001b[0m, \u001b[91mcause\u001b[0m, \u001b[91minfection\u001b[0m\n",
      "============================\n",
      "RESULT: In humans , \u001b[1m[\u001b[94mARG1 CHIKV infections ]\u001b[0m cause a \u001b[1m[\u001b[94mARG2 debilitating disease with acute febrile illness and long-term polyarthralgia ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]infections\u001b[0m, \u001b[92m[c]CHIKV\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91macute\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91m,\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]acute\u001b[0m, \u001b[91ma\u001b[0m, \u001b[92m[c]polyarthralgia\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 MERS-CoV ]\u001b[0m induces \u001b[1m[\u001b[94mARG2 acute pneumonia similar to that caused by SARS-CoV, ]\u001b[0m and is sometimes accompanied with \u001b[1m[\u001b[94mARG2 renal failure ]\u001b[0m ( Danielsson and Catchpole , 2012 ; Zaki et al. , 2012 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]MERS-CoV\u001b[0m, \u001b[91macute\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91minduces\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mby\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[94m[p]acute\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minduces\u001b[0m, \u001b[92m[c]failure\u001b[0m, \u001b[92m[c]renal\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mMERS-CoV\u001b[0m, \u001b[94m[p]similar\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 FIV infection ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 progressive immunosuppression ]\u001b[0m that results in the development of the \u001b[1m[\u001b[94mARG2 acquired immunodeficiency syndrome ( AIDS ) ]\u001b[0m in cats , which , similar to human HIV infection , increases susceptibility to secondary and opportunistic infections .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]FIV\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mHIV\u001b[0m, \u001b[91mprogressive\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mcats\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mhuman\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]progressive\u001b[0m, \u001b[92m[c]progressive\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[92m[c]immunosuppression\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mcats\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mdevelopment\u001b[0m, \u001b[91msusceptibility\u001b[0m\n",
      "============================\n",
      "RESULT: In humans , \u001b[1m[\u001b[94mARG1 JEV infection ]\u001b[0m can cause \u001b[1m[\u001b[94mARG2 Japanese encephalitis ( JE ) with severe central nervous system disorders ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]JEV\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mcause\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91m(\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]severe\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[92m[c]disorders\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[92m[c]central\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[92m[c]nervous\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mcause\u001b[0m\n",
      "============================\n",
      "RESULT: In immunocompetent adults , \u001b[1m[\u001b[94mARG1 primary infection with HHV-6 ]\u001b[0m can produce a \u001b[1m[\u001b[94mARG2 mononucleosis-like illness ]\u001b[0m and , more rarely , \u001b[1m[\u001b[94mARG2 severe disease , including encephalitis ]\u001b[0m [ Stoeckle , 2000 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]primary\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91mencephalitis\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91madults\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]encephalitis\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mprimary\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91madults\u001b[0m, \u001b[94m[p]severe\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Infection with MV ]\u001b[0m typically results in an \u001b[1m[\u001b[94mARG2 acute febrile illness and rash ]\u001b[0m due to viral replication first in mono-and lymphocytic cells , and then in a variety of tissues ( Katz 1995 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]Infection\u001b[0m, \u001b[92m[c]MV\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mreplication\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91macute\u001b[0m, \u001b[91m1995\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mInfection\u001b[0m, \u001b[92m[c]febrile\u001b[0m, \u001b[94m[p]acute\u001b[0m, \u001b[91man\u001b[0m, \u001b[92m[c]rash\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mMV\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 BRV ]\u001b[0m is a lytic infection and \u001b[1m[\u001b[94mARG2 destruction of infected mucosal epithelial cells ]\u001b[0m is an important component of disease pathogenesis .\n",
      "ARG1 PREDS: \u001b[92m[c]BRV\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mmucosal\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mpathogenesis\u001b[0m, \u001b[91mepithelial\u001b[0m, \u001b[91mlytic\u001b[0m, \u001b[91mis\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mdisease\u001b[0m, \u001b[94m[p]mucosal\u001b[0m, \u001b[91mpathogenesis\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]epithelial\u001b[0m, \u001b[94m[p]cells\u001b[0m, \u001b[91mBRV\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]destruction\u001b[0m, \u001b[94m[p]of\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 FIV infection ]\u001b[0m , in domestic cats , \u001b[1m[\u001b[94mARG2 causes a variable immunodeficiency syndrome characterized ]\u001b[0m \u001b[1m[\u001b[94mARG2 by recurrent gingivitis-stomatitis , cachexia , wasting , neurology , and an increased incidence of tumor development ]\u001b[0m [ 1 , 4 , 48 , 76 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]FIV\u001b[0m, \u001b[91mcats\u001b[0m, \u001b[91mdomestic\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91min\u001b[0m, \u001b[91msyndrome\u001b[0m, \u001b[91mtumor\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mrecurrent\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]syndrome\u001b[0m, \u001b[94m[p]a\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]recurrent\u001b[0m, \u001b[92m[c]wasting\u001b[0m, \u001b[94m[p]by\u001b[0m, \u001b[91mcats\u001b[0m, \u001b[92m[c]neurology\u001b[0m, \u001b[91mdomestic\u001b[0m, \u001b[92m[c]tumor\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Adenovirus infection ]\u001b[0m can result in \u001b[1m[\u001b[94mARG2 severe respiratory disease ]\u001b[0m in lung transplant recipients , including \u001b[1m[\u001b[94mARG2 rapidly progressive , necrotizing and potentially fatal pneumonia ]\u001b[0m , as well as \u001b[1m[\u001b[94mARG2 development of chronic lung disease with fibrosis and bronchiectasis ]\u001b[0m ( Liu et al. 2010 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]Adenovirus\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mresult\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mtransplant\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[92m[c]pneumonia\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91min\u001b[0m, \u001b[94m[p]development\u001b[0m, \u001b[91mAdenovirus\u001b[0m, \u001b[92m[c]disease\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Filovirusinduced disease ]\u001b[0m begins with \u001b[1m[\u001b[94mARG2 flu-like symptoms ]\u001b[0m and progresses rapidly to the final stages of viral hemorrhagic fever infection , which are characterized by \u001b[1m[\u001b[94mARG2 fever , hemorrhage , and hypotensive shock ]\u001b[0m ( Groseth et al. , 2007 ; Zampieri et al. , 2007 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[92m[c]Filovirusinduced\u001b[0m, \u001b[91mfever\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mshock\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mdisease\u001b[0m, \u001b[92m[c]shock\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]symptoms\u001b[0m, \u001b[92m[c]hemorrhage\u001b[0m, \u001b[91mFilovirusinduced\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mof\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91m(\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 PEDV ]\u001b[0m infects the epithelium of the small intestine , an environment rich in proteases , and causes \u001b[1m[\u001b[94mARG2 atrophy of the villi resulting in diarrhea and dehydration ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]PEDV\u001b[0m, \u001b[91mdiarrhea\u001b[0m, \u001b[92m[c]PEDV\u001b[0m, \u001b[91mintestine\u001b[0m, \u001b[91mepithelium\u001b[0m, \u001b[91mproteases\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mdehydration\u001b[0m, \u001b[91matrophy\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]diarrhea\u001b[0m, \u001b[92m[c]atrophy\u001b[0m, \u001b[92m[c]dehydration\u001b[0m, \u001b[91mPEDV\u001b[0m, \u001b[91mepithelium\u001b[0m, \u001b[91mintestine\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mproteases\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[94m[p]of\u001b[0m\n",
      "============================\n",
      "RESULT: In humans , \u001b[1m[\u001b[94mARG1 coronavirus infection ]\u001b[0m results in \u001b[1m[\u001b[94mARG2 respiratory tract complications ]\u001b[0m with varying degree of severity and has been associated \u001b[1m[\u001b[94mARG2 with gastroenteritis ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]coronavirus\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mgastroenteritis\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mtract\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]gastroenteritis\u001b[0m, \u001b[92m[c]complications\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[92m[c]tract\u001b[0m, \u001b[91mseverity\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mhumans\u001b[0m\n",
      "============================\n",
      "RESULT: Humans infected with \u001b[1m[\u001b[94mARG1 RVFV ]\u001b[0m usually develop \u001b[1m[\u001b[94mARG2 an acute febrile myalgic syndrome ]\u001b[0m ; however , a small percentage of patients have a lethal illness that results in \u001b[1m[\u001b[94mARG2 hepatic damage , hemorrhagic fever-like illness , encephalitis and/or retinal vasculitis ]\u001b[0m [ 8 ] .\n",
      "ARG1 PREDS: \u001b[91minfected\u001b[0m, \u001b[92m[c]RVFV\u001b[0m, \u001b[91mHumans\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91macute\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]syndrome\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[91mHumans\u001b[0m, \u001b[92m[c]damage\u001b[0m, \u001b[92m[c]acute\u001b[0m, \u001b[92m[c]febrile\u001b[0m, \u001b[94m[p]an\u001b[0m, \u001b[92m[c]encephalitis\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 PRRSV ]\u001b[0m increases the \u001b[1m[\u001b[94mARG2 susceptibility of the host to a wide range of viral and bacterial respiratory pathogens ]\u001b[0m , resulting in \u001b[1m[\u001b[94mARG2 increased severity of clinical signs and lung lesions ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]PRRSV\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mincreases\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mpathogens\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mseverity\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]severity\u001b[0m, \u001b[92m[c]clinical\u001b[0m, \u001b[91mincreases\u001b[0m, \u001b[92m[c]lesions\u001b[0m, \u001b[92m[c]lung\u001b[0m, \u001b[94m[p]respiratory\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]host\u001b[0m, \u001b[92m[c]increased\u001b[0m, \u001b[92m[c]signs\u001b[0m\n",
      "============================\n",
      "RESULT: In humans , the \u001b[1m[\u001b[94mARG1 virus ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 a lower respiratory tract disease ]\u001b[0m and may progress to \u001b[1m[\u001b[94mARG2 ARDS , multiorgan failure , and death ]\u001b[0m in severe cases .\n",
      "ARG1 PREDS: \u001b[92m[c]virus\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91msevere\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[94m[p]a\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[92m[c]ARDS\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mcases\u001b[0m\n",
      "============================\n",
      "RESULT: In most cases , \u001b[1m[\u001b[94mARG1 MERS-CoV ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 severe infection in the lower respiratory tract ]\u001b[0m in humans .\n",
      "ARG1 PREDS: \u001b[92m[c]MERS-CoV\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mmost\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mIn\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[94m[p]in\u001b[0m, \u001b[91mMERS-CoV\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91min\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mmost\u001b[0m\n",
      "============================\n",
      "RESULT: In humans , \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 interstitial pneumonia with fever ]\u001b[0m and sometimes \u001b[1m[\u001b[94mARG2 diarrhea ]\u001b[0m ( 3 , 4 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91minterstitial\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mdiarrhea\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mfever\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[92m[c]diarrhea\u001b[0m, \u001b[92m[c]interstitial\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mand\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Infection ]\u001b[0m of humans is characterized by a rapid and extensive spread of the virus in several organs with symptoms including \u001b[1m[\u001b[94mARG2 respiratory distress and encephalitis ]\u001b[0m ( 46 ) .\n",
      "ARG1 PREDS: \u001b[91mvirus\u001b[0m, \u001b[92m[c]Infection\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mspread\u001b[0m, \u001b[91mencephalitis\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mby\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mis\u001b[0m, \u001b[92m[c]encephalitis\u001b[0m, \u001b[91mInfection\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mspread\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91morgans\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[92m[c]distress\u001b[0m, \u001b[91msymptoms\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 The HPeV-1 infection ]\u001b[0m is mostly represented by \u001b[1m[\u001b[94mARG2 a mild respiratory or gastrointestinal infection, ]\u001b[0m but sometimes becomes clinically severe , leading to \u001b[1m[\u001b[94mARG2 sepsis-like illness and central nervous system infection ]\u001b[0m in infants .\n",
      "ARG1 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[92m[c]HPeV-1\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mgastrointestinal\u001b[0m, \u001b[91minfants\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]gastrointestinal\u001b[0m, \u001b[91minfants\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: The pathogenesis of \u001b[1m[\u001b[94mARG1 Ebola virus disease ( EVD ) ]\u001b[0m is not well understood , but likely results from \u001b[1m[\u001b[94mARG2 overwhelming cytopathic damage ]\u001b[0m due to the ability of Ebola virus to replicate throughout many different tissues of the body , \u001b[1m[\u001b[94mARG2 dysregulation of the immune response , and profound hypovolemia ]\u001b[0m [ 9 ] .\n",
      "ARG1 PREDS: \u001b[91mvirus\u001b[0m, \u001b[94m[p]disease\u001b[0m, \u001b[92m[c]virus\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mbody\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mof\u001b[0m, \u001b[92m[c]EVD\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91moverwhelming\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]damage\u001b[0m, \u001b[91mbody\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[92m[c]hypovolemia\u001b[0m, \u001b[94m[p]overwhelming\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]overwhelming\u001b[0m, \u001b[94m[p]profound\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mEVD\u001b[0m\n",
      "============================\n",
      "RESULT: Currently , humans infected with \u001b[1m[\u001b[94mARG1 MERS-CoV ]\u001b[0m have been reported to develop a \u001b[1m[\u001b[94mARG2 severe acute respiratory illness ]\u001b[0m with symptoms of \u001b[1m[\u001b[94mARG2 fever , cough , shortness of breath , and often , renal failure ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]MERS-CoV\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mCurrently\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91macute\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mCurrently\u001b[0m, \u001b[91ma\u001b[0m, \u001b[92m[c]acute\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mbeen\u001b[0m\n",
      "============================\n",
      "RESULT: As discussed above , \u001b[1m[\u001b[94mARG1 coxsackievirus B3 ( CVB3 ) infection ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 myocarditis ]\u001b[0m in human beings as well as in male BALB/c mice .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]coxsackievirus\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mmyocarditis\u001b[0m, \u001b[91mAs\u001b[0m, \u001b[92m[c]B3\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91min\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]myocarditis\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mAs\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91mmale\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m(\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 PEDV infections ]\u001b[0m cause acute , \u001b[1m[\u001b[94mARG2 severe atrophic enteritis accompanied by viremia ]\u001b[0m that leads to \u001b[1m[\u001b[94mARG2 profound diarrhea and vomiting, ]\u001b[0m followed by \u001b[1m[\u001b[94mARG2 extensive dehydration ]\u001b[0m , which is the major cause of death in nursing piglets .\n",
      "ARG1 PREDS: \u001b[92m[c]PEDV\u001b[0m, \u001b[92m[c]infections\u001b[0m, \u001b[91mnursing\u001b[0m, \u001b[91menteritis\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mpiglets\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mnursing\u001b[0m, \u001b[91macute\u001b[0m, \u001b[91mextensive\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]enteritis\u001b[0m, \u001b[92m[c]dehydration\u001b[0m, \u001b[92m[c]diarrhea\u001b[0m, \u001b[94m[p]extensive\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[94m[p]profound\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mdeath\u001b[0m\n",
      "============================\n",
      "RESULT: During infection , \u001b[1m[\u001b[94mARG1 JEV ]\u001b[0m invades the central nervous system , wherein virus replication triggers \u001b[1m[\u001b[94mARG2 a massive inflammatory response ]\u001b[0m , and subsequently causes \u001b[1m[\u001b[94mARG2 neuronal cell death ]\u001b[0m ( 5 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]JEV\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mreplication\u001b[0m, \u001b[91mDuring\u001b[0m, \u001b[91mneuronal\u001b[0m, \u001b[91mnervous\u001b[0m, \u001b[91mcentral\u001b[0m, \u001b[91minflammatory\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]inflammatory\u001b[0m, \u001b[92m[c]neuronal\u001b[0m, \u001b[91mnervous\u001b[0m, \u001b[91mcentral\u001b[0m, \u001b[92m[c]death\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]massive\u001b[0m, \u001b[92m[c]response\u001b[0m, \u001b[91mreplication\u001b[0m, \u001b[92m[c]cell\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Primary HHV-6 infection ]\u001b[0m causes \u001b[1m[\u001b[94mARG2 undifferentiated febrile illness and exanthem subitum ( roseola infantum or sixth disease ) ]\u001b[0m , \u001b[1m[\u001b[94mARG2 an acute illness with high fever and rash ]\u001b[0m that typically resolves in three to seven days [ 49 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]Primary\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[92m[c]HHV-6\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91millness\u001b[0m, \u001b[92m[c]Primary\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]febrile\u001b[0m, \u001b[92m[c]rash\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mPrimary\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[94m[p](\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: After an incubation period of 5 to 14 days , \u001b[1m[\u001b[94mARG1 SARS-CoV-2-infected people ]\u001b[0m commonly manifest \u001b[1m[\u001b[94mARG2 features of pneumonia ]\u001b[0m , including \u001b[1m[\u001b[94mARG2 fever , dry cough , dyspnoea , myalgia and fatigue ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]people\u001b[0m, \u001b[92m[c]SARS-CoV-2-infected\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mAfter\u001b[0m, \u001b[91mcommonly\u001b[0m, \u001b[91man\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mfatigue\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mfeatures\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[92m[c]fatigue\u001b[0m, \u001b[91mpeople\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[92m[c]cough\u001b[0m, \u001b[91mAfter\u001b[0m, \u001b[91mSARS-CoV-2-infected\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91mcommonly\u001b[0m, \u001b[94m[p]features\u001b[0m\n",
      "============================\n",
      "RESULT: After an incubation period of 2 to 3 days , \u001b[1m[\u001b[94mARG1 patients who have pneumonic plague ]\u001b[0m typically develop \u001b[1m[\u001b[94mARG2 fulminant pneumonia , with malaise , high fever , cough , hemoptysis , and septicemia with ecchymoses and extremity necrosis ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[94m[p]who\u001b[0m, \u001b[91mAfter\u001b[0m, \u001b[94m[p]have\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91man\u001b[0m, \u001b[91mnecrosis\u001b[0m, \u001b[92m[c]plague\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[92m[c]necrosis\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[92m[c]fulminant\u001b[0m, \u001b[92m[c]septicemia\u001b[0m, \u001b[91mAfter\u001b[0m, \u001b[94m[p]with\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Patients suffering from severe DENV infection ]\u001b[0m often exhibit \u001b[1m[\u001b[94mARG2 encephalopathy and encephalitis ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Patients\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91mexhibit\u001b[0m, \u001b[91moften\u001b[0m, \u001b[92m[c]DENV\u001b[0m, \u001b[94m[p]from\u001b[0m, \u001b[91mencephalitis\u001b[0m, \u001b[94m[p]suffering\u001b[0m, \u001b[94m[p]severe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]encephalitis\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[92m[c]encephalopathy\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mexhibit\u001b[0m, \u001b[91mDENV\u001b[0m, \u001b[91mfrom\u001b[0m, \u001b[91moften\u001b[0m\n",
      "============================\n",
      "RESULT: Following an incubation period of usually 4 - 5 days , \u001b[1m[\u001b[94mARG1 patients infected with SARS-CoV ]\u001b[0m often present with \u001b[1m[\u001b[94mARG2 symptoms of fever , headache , and myalgias ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[94m[p]infected\u001b[0m, \u001b[91mFollowing\u001b[0m, \u001b[91moften\u001b[0m, \u001b[91mpresent\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91man\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mfever\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[94m[p]symptoms\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]headache\u001b[0m, \u001b[91mpresent\u001b[0m, \u001b[91mFollowing\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[94m[p]of\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Cats with FIP ]\u001b[0m show \u001b[1m[\u001b[94mARG2 nonspecific clinical signs such as fever , weight loss and anorexia ]\u001b[0m , often accompanied by \u001b[1m[\u001b[94mARG2 body cavity effusions and/or ocular and neurological signs ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Cats\u001b[0m, \u001b[91mshow\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mnonspecific\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[92m[c]FIP\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91msigns\u001b[0m, \u001b[91mfever\u001b[0m, \u001b[91msuch\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]clinical\u001b[0m, \u001b[92m[c]nonspecific\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91mshow\u001b[0m, \u001b[91mCats\u001b[0m, \u001b[91mFIP\u001b[0m, \u001b[92m[c]signs\u001b[0m, \u001b[92m[c]signs\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Cats with signs from FIV ]\u001b[0m often have \u001b[1m[\u001b[94mARG2 lethargy , anorexia and weight loss ]\u001b[0m associated with secondary infections of the skin , and gastrointestinal or respiratory tracts .\n",
      "ARG1 PREDS: \u001b[92m[c]Cats\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91moften\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[92m[c]FIV\u001b[0m, \u001b[94m[p]from\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[94m[p]signs\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[94m[p]from\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mhave\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mFIV\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91msecondary\u001b[0m, \u001b[91mCats\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[91moften\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mfrom\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Enteric FCoV infection ]\u001b[0m typically results in \u001b[1m[\u001b[94mARG2 inappetence and/or mild gastrointestinal signs such as vomiting and diarrhea ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]Enteric\u001b[0m, \u001b[91mresults\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[92m[c]FCoV\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mmild\u001b[0m, \u001b[91msigns\u001b[0m, \u001b[91mvomiting\u001b[0m, \u001b[91mdiarrhea\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mEnteric\u001b[0m, \u001b[91mresults\u001b[0m, \u001b[94m[p]mild\u001b[0m, \u001b[92m[c]diarrhea\u001b[0m, \u001b[92m[c]vomiting\u001b[0m, \u001b[92m[c]signs\u001b[0m, \u001b[92m[c]gastrointestinal\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mFCoV\u001b[0m\n",
      "============================\n",
      "RESULT: Most \u001b[1m[\u001b[94mARG1 patients with MERS ]\u001b[0m develop \u001b[1m[\u001b[94mARG2 severe acute respiratory illness accompanied by fever , cough , and shortness of breath ]\u001b[0m [ 50 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[91mMost\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[92m[c]MERS\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91millness\u001b[0m, \u001b[91macute\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]respiratory\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[92m[c]acute\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[92m[c]cough\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91mMERS\u001b[0m, \u001b[94m[p]by\u001b[0m, \u001b[91mpatients\u001b[0m\n",
      "============================\n",
      "RESULT: The \u001b[1m[\u001b[94mARG1 terminal stages of Ebola virus infection ]\u001b[0m usually include \u001b[1m[\u001b[94mARG2 diffuse bleeding , and hypotensive shock ]\u001b[0m accounts for many Ebola virus fatalities .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]stages\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91musually\u001b[0m, \u001b[91mbleeding\u001b[0m, \u001b[91mshock\u001b[0m, \u001b[91minclude\u001b[0m, \u001b[92m[c]virus\u001b[0m, \u001b[92m[c]terminal\u001b[0m, \u001b[91mdiffuse\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]bleeding\u001b[0m, \u001b[92m[c]diffuse\u001b[0m, \u001b[92m[c]shock\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91minclude\u001b[0m, \u001b[91mstages\u001b[0m, \u001b[91mterminal\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91musually\u001b[0m\n",
      "============================\n",
      "RESULT: In \u001b[1m[\u001b[94mARG1 rats ]\u001b[0m , infection is usually asymptomatic , although \u001b[1m[\u001b[94mARG2 nonspecific clinical signs such as weight loss and dyspnea ]\u001b[0m may occur .\n",
      "ARG1 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]rats\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mdyspnea\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mnonspecific\u001b[0m, \u001b[91masymptomatic\u001b[0m, \u001b[91moccur\u001b[0m, \u001b[91mweight\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]clinical\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]dyspnea\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]nonspecific\u001b[0m, \u001b[92m[c]weight\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[92m[c]signs\u001b[0m, \u001b[91moccur\u001b[0m\n",
      "============================\n",
      "RESULT: Following an average incubation period of 20 days , \u001b[1m[\u001b[94mARG1 infected patients ]\u001b[0m can present with \u001b[1m[\u001b[94mARG2 severe headache , fever , chills , fatigue , and myalgia ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[92m[c]infected\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mpresent\u001b[0m, \u001b[91mFollowing\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mdays\u001b[0m, \u001b[91mheadache\u001b[0m, \u001b[91maverage\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[92m[c]headache\u001b[0m, \u001b[91mpresent\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[92m[c]myalgia\u001b[0m, \u001b[92m[c]fatigue\u001b[0m, \u001b[92m[c]fever\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Patients infected with EVD ]\u001b[0m rapidly deteriorate and commonly present with \u001b[1m[\u001b[94mARG2 gastrointestinal symptoms including vomiting , diarrhea and dehydration ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Patients\u001b[0m, \u001b[94m[p]infected\u001b[0m, \u001b[91mrapidly\u001b[0m, \u001b[92m[c]EVD\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mrapidly\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mcommonly\u001b[0m, \u001b[91mincluding\u001b[0m, \u001b[91msymptoms\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mPatients\u001b[0m, \u001b[92m[c]symptoms\u001b[0m, \u001b[92m[c]dehydration\u001b[0m, \u001b[91mrapidly\u001b[0m, \u001b[92m[c]vomiting\u001b[0m, \u001b[92m[c]gastrointestinal\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[92m[c]diarrhea\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[94m[p]including\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Adult rabbits ]\u001b[0m usually develop a \u001b[1m[\u001b[94mARG2 chronic disease course ]\u001b[0m , which can lead to \u001b[1m[\u001b[94mARG2 intestinal fi brosis , liver necrosis and stenosis , and myocardial disease ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]rabbits\u001b[0m, \u001b[92m[c]Adult\u001b[0m, \u001b[91musually\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mintestinal\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mchronic\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mcourse\u001b[0m, \u001b[91mcan\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]chronic\u001b[0m, \u001b[92m[c]intestinal\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]course\u001b[0m, \u001b[92m[c]liver\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91ma\u001b[0m, \u001b[92m[c]necrosis\u001b[0m, \u001b[91mrabbits\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Cats ]\u001b[0m are primarily infected subclinically , but \u001b[1m[\u001b[94mARG2 gastrointestinal disease manifested as enterocolitis and endotoxemia ]\u001b[0m can occur and is initially associated with \u001b[1m[\u001b[94mARG2 fever , malaise , and anorexia followed by vomiting , abdominal pain , and diarrhoea ]\u001b[0m [ 7 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]Cats\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mbut\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91msubclinically\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mprimarily\u001b[0m, \u001b[91m7\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mbut\u001b[0m, \u001b[91mCats\u001b[0m, \u001b[92m[c]gastrointestinal\u001b[0m, \u001b[92m[c]diarrhoea\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Affected rabbits ]\u001b[0m usually develop \u001b[1m[\u001b[94mARG2 sepsis ]\u001b[0m , which quickly leads to death ; however , \u001b[1m[\u001b[94mARG2 diarrhea ]\u001b[0m may occur as well .\n",
      "ARG1 PREDS: \u001b[92m[c]rabbits\u001b[0m, \u001b[92m[c]Affected\u001b[0m, \u001b[91msepsis\u001b[0m, \u001b[91mdiarrhea\u001b[0m, \u001b[91musually\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91m;\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[91moccur\u001b[0m, \u001b[91mmay\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]sepsis\u001b[0m, \u001b[92m[c]diarrhea\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[91moccur\u001b[0m, \u001b[91mrabbits\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mAffected\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91m;\u001b[0m, \u001b[91musually\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Common marmosets with measles infection ]\u001b[0m become clinically apparent with \u001b[1m[\u001b[94mARG2 lethargy , facial edema , and nasal discharge ]\u001b[0m and occasionally develop an \u001b[1m[\u001b[94mARG2 exanthema ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]marmosets\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[92m[c]measles\u001b[0m, \u001b[92m[c]Common\u001b[0m, \u001b[91mbecome\u001b[0m, \u001b[92m[c]Common\u001b[0m, \u001b[91man\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mclinically\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91man\u001b[0m, \u001b[91mmeasles\u001b[0m, \u001b[92m[c]nasal\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mbecome\u001b[0m, \u001b[92m[c]discharge\u001b[0m, \u001b[91mclinically\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[92m[c]facial\u001b[0m\n",
      "============================\n",
      "RESULT: In \u001b[1m[\u001b[94mARG1 humans ]\u001b[0m , VEEV infection causes \u001b[1m[\u001b[94mARG2 a sudden onset of malaise , fever , chills , headache , and sore throat ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]humans\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91msudden\u001b[0m, \u001b[91monset\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mVEEV\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mheadache\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]sudden\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[94m[p]onset\u001b[0m, \u001b[94m[p]a\u001b[0m, \u001b[92m[c]headache\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Humans infected with RVFV ]\u001b[0m usually develop \u001b[1m[\u001b[94mARG2 an acute febrile myalgic syndrome ]\u001b[0m ; however , a small percentage of patients have a \u001b[1m[\u001b[94mARG2 lethal illness that results in hepatic damage , hemorrhagic fever-like illness , encephalitis and/or retinal vasculitis ]\u001b[0m [ 8 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]Humans\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]infected\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91musually\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91m;\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91millness\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]syndrome\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[92m[c]febrile\u001b[0m, \u001b[94m[p]acute\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]an\u001b[0m, \u001b[91mHumans\u001b[0m, \u001b[92m[c]encephalitis\u001b[0m, \u001b[92m[c]retinal\u001b[0m\n",
      "============================\n",
      "RESULT: In \u001b[1m[\u001b[94mARG1 humans ]\u001b[0m , infection is associated with \u001b[1m[\u001b[94mARG2 fever and liver damage ]\u001b[0m , but a subset of patients progress to \u001b[1m[\u001b[94mARG2 hemorrhagic fever , encephalitis , ocular disease or death ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mpatients\u001b[0m, \u001b[92m[c]humans\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mfever\u001b[0m, \u001b[91mbut\u001b[0m, \u001b[91mliver\u001b[0m, \u001b[91mdamage\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]liver\u001b[0m, \u001b[92m[c]damage\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]encephalitis\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]disease\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]hemorrhagic\u001b[0m\n",
      "============================\n",
      "RESULT: After an incubation period of 9 - 12 days , MERS generally presents in \u001b[1m[\u001b[94mARG1 humans ]\u001b[0m as \u001b[1m[\u001b[94mARG2 a lower respiratory infection with fever ( often with chills or rigors ) , dry or productive cough and dyspnea ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]humans\u001b[0m, \u001b[91mgenerally\u001b[0m, \u001b[91mAfter\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mpresents\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mMERS\u001b[0m, \u001b[91man\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mdyspnea\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]dyspnea\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]cough\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mMERS\u001b[0m, \u001b[91mhumans\u001b[0m, \u001b[91mgenerally\u001b[0m, \u001b[94m[p]a\u001b[0m, \u001b[91mAfter\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Patients with bubonic plague ]\u001b[0m usually develop \u001b[1m[\u001b[94mARG2 symptoms of fever , headache , chills , and swollen , extremely tender lymph nodes ( buboes ) ]\u001b[0m within 2 to 6 days after contact with the pathogen .\n",
      "ARG1 PREDS: \u001b[92m[c]Patients\u001b[0m, \u001b[91musually\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mcontact\u001b[0m, \u001b[91mpathogen\u001b[0m, \u001b[92m[c]plague\u001b[0m, \u001b[91mdays\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]symptoms\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]lymph\u001b[0m, \u001b[91mpathogen\u001b[0m, \u001b[91musually\u001b[0m, \u001b[92m[c]headache\u001b[0m, \u001b[91mplague\u001b[0m, \u001b[94m[p]of\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Symptomatic CHIKV infection ]\u001b[0m often manifests itself by \u001b[1m[\u001b[94mARG2 short-lived fever and recurrent joint pain ]\u001b[0m , which can last for months to years ( 10 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]Symptomatic\u001b[0m, \u001b[91moften\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91m(\u001b[0m, \u001b[92m[c]CHIKV\u001b[0m, \u001b[91mjoint\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mfever\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mSymptomatic\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]joint\u001b[0m, \u001b[92m[c]pain\u001b[0m, \u001b[92m[c]recurrent\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91moften\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Pneumonia caused by SARS-CoV ]\u001b[0m typically has an insidious onset , and \u001b[1m[\u001b[94mARG2 respiratory symptoms ]\u001b[0m worsen slowly but steadily during the first 10 to 15 days [ 10•• ] .\n",
      "ARG1 PREDS: \u001b[92m[c]Pneumonia\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91m[\u001b[0m, \u001b[94m[p]by\u001b[0m, \u001b[94m[p]by\u001b[0m, \u001b[94m[p]caused\u001b[0m, \u001b[91mhas\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mPneumonia\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[92m[c]symptoms\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91monset\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mcaused\u001b[0m, \u001b[91mby\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Those infected with SARS ]\u001b[0m suffer \u001b[1m[\u001b[94mARG2 fever , cough , muscle aches , and shortness of breath ]\u001b[0m and often progress to \u001b[1m[\u001b[94mARG2 severe lung inflammation ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Those\u001b[0m, \u001b[92m[c]infected\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91msuffer\u001b[0m, \u001b[91mfever\u001b[0m, \u001b[92m[c]SARS\u001b[0m, \u001b[91minflammation\u001b[0m, \u001b[91mcough\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]lung\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[94m[p]inflammation\u001b[0m, \u001b[92m[c]fever\u001b[0m, \u001b[92m[c]cough\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mThose\u001b[0m, \u001b[91msuffer\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mSARS\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 lung cancer ]\u001b[0m are highly susceptible to \u001b[1m[\u001b[94mARG2 infection ]\u001b[0m compared to healthy individuals because of systemic immunosuppression induced by malignancy and anticancer therapy .\n",
      "ARG1 PREDS: \u001b[92m[c]cancer\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]lung\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mmalignancy\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mcancer\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mmalignancy\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91msystemic\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 lung cancer ]\u001b[0m are highly susceptible to \u001b[1m[\u001b[94mARG2 infection ]\u001b[0m compared to healthy individuals because of systemic immunosuppression induced by malignancy and anticancer therapy .\n",
      "ARG1 PREDS: \u001b[92m[c]cancer\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]lung\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mmalignancy\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mcancer\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mmalignancy\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91msystemic\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 ARDS ]\u001b[0m triggered by viral infection , in particular influenza , are prone to \u001b[1m[\u001b[94mARG2 invasive aspergillosis ]\u001b[0m even in absence of prior immunodeficiency .\n",
      "ARG1 PREDS: \u001b[92m[c]ARDS\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mimmunodeficiency\u001b[0m, \u001b[91mprior\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mviral\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[94m[p]invasive\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mare\u001b[0m, \u001b[94m[p]invasive\u001b[0m, \u001b[94m[p]aspergillosis\u001b[0m, \u001b[91mARDS\u001b[0m, \u001b[91mprior\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: Individuals with \u001b[1m[\u001b[94mARG1 SCD ]\u001b[0m are strongly susceptible to \u001b[1m[\u001b[94mARG2 encapsulated bacterial organisms ]\u001b[0m such as S. pneumoniae , a common colonizer of the nasopharynx in healthy children .\n",
      "ARG1 PREDS: \u001b[92m[c]SCD\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91mhealthy\u001b[0m, \u001b[91mstrongly\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mbacterial\u001b[0m, \u001b[91msuch\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]organisms\u001b[0m, \u001b[92m[c]bacterial\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mSCD\u001b[0m, \u001b[91mto\u001b[0m, \u001b[92m[c]encapsulated\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mstrongly\u001b[0m\n",
      "============================\n",
      "RESULT: Individuals with \u001b[1m[\u001b[94mARG1 diabetes , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease ]\u001b[0m are especially susceptible to \u001b[1m[\u001b[94mARG2 infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]diabetes\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]hemochromatosis\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[92m[c]disorders\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mespecially\u001b[0m, \u001b[91mdiabetes\u001b[0m, \u001b[91msusceptible\u001b[0m, \u001b[91mincluding\u001b[0m, \u001b[91mand\u001b[0m\n",
      "============================\n",
      "RESULT: Moreover , children \u001b[1m[\u001b[94mARG1 receiving immunomodulatory or immunosuppressive therapies due to malignancy , transplantation , or autoimmune disease ]\u001b[0m are more susceptible to \u001b[1m[\u001b[94mARG2 viral infection or reactivation ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mchildren\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mMoreover\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[92m[c]malignancy\u001b[0m, \u001b[91mreactivation\u001b[0m, \u001b[92m[c]autoimmune\u001b[0m, \u001b[92m[c]receiving\u001b[0m, \u001b[92m[c]therapies\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]viral\u001b[0m, \u001b[92m[c]reactivation\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[94m[p]or\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mMoreover\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mmore\u001b[0m\n",
      "============================\n",
      "RESULT: Accordingly , \u001b[1m[\u001b[94mARG1 young children ]\u001b[0m , compared with adult \u001b[1m[\u001b[94mARG1 transplant recipients ]\u001b[0m , are at higher risk of acquiring \u001b[1m[\u001b[94mARG2 primary infection with many organisms ]\u001b[0m after they are immunosuppressed , which can lead to increased severity .\n",
      "ARG1 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]transplant\u001b[0m, \u001b[92m[c]children\u001b[0m, \u001b[92m[c]recipients\u001b[0m, \u001b[91mseverity\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mprimary\u001b[0m, \u001b[91mimmunosuppressed\u001b[0m, \u001b[91mafter\u001b[0m, \u001b[91mthey\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]primary\u001b[0m, \u001b[94m[p]organisms\u001b[0m, \u001b[91mseverity\u001b[0m, \u001b[91macquiring\u001b[0m, \u001b[94m[p]many\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[91mincreased\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mtransplant\u001b[0m\n",
      "============================\n",
      "RESULT: On one hand , \u001b[1m[\u001b[94mARG1 elderly patients ]\u001b[0m are at risk for \u001b[1m[\u001b[94mARG2 gram-negative and anaerobic polymicrobial aspiration pneumonia ]\u001b[0m , and on the other hand are more prone to \u001b[1m[\u001b[94mARG2 bacterial superinfections ]\u001b[0m following \u001b[1m[\u001b[94mARG1 influenza infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]elderly\u001b[0m, \u001b[92m[c]influenza\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mbacterial\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91msuperinfections\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]pneumonia\u001b[0m, \u001b[92m[c]bacterial\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[92m[c]superinfections\u001b[0m, \u001b[91mfollowing\u001b[0m, \u001b[92m[c]aspiration\u001b[0m, \u001b[92m[c]bacterial\u001b[0m, \u001b[91melderly\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 cancer ]\u001b[0m are known to be at an increased risk for \u001b[1m[\u001b[94mARG2 community-acquired respiratory viruses ]\u001b[0m , such as \u001b[1m[\u001b[94mARG2 influenza ]\u001b[0m , because of their frequently observed immunocompromised state .\n",
      "ARG1 PREDS: \u001b[92m[c]cancer\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mobserved\u001b[0m, \u001b[91mstate\u001b[0m, \u001b[91mknown\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mviruses\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]influenza\u001b[0m, \u001b[92m[c]viruses\u001b[0m, \u001b[91mcancer\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mobserved\u001b[0m, \u001b[91mrisk\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mknown\u001b[0m\n",
      "============================\n",
      "RESULT: However , \u001b[1m[\u001b[94mARG1 immunocompromised patients ]\u001b[0m , including those with \u001b[1m[\u001b[94mARG1 HIV/AIDS and patients taking immunosuppressants post-transplant ]\u001b[0m , are at an increased risk for \u001b[1m[\u001b[94mARG2 viral and fungal pneumonia ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]post-transplant\u001b[0m, \u001b[91m,\u001b[0m, \u001b[94m[p]patients\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[92m[c]HIV/AIDS\u001b[0m, \u001b[92m[c]immunocompromised\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[92m[c]viral\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]fungal\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mrisk\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mpost-transplant\u001b[0m\n",
      "============================\n",
      "RESULT: Although the incidence of \u001b[1m[\u001b[94mARG2 RSV ]\u001b[0m infection is low among patients with \u001b[1m[\u001b[94mARG1 AML ]\u001b[0m , it is associated with \u001b[1m[\u001b[94mARG2 high mortality ]\u001b[0m in \u001b[1m[\u001b[94mARG1 children with AML ]\u001b[0m [ 21 ] , and it is well known that \u001b[1m[\u001b[94mARG1 infants , both immunocompetent and immunocompromised ]\u001b[0m , are particularly vulnerable to \u001b[1m[\u001b[94mARG2 RSV ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]AML\u001b[0m, \u001b[92m[c]AML\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mRSV\u001b[0m, \u001b[91mRSV\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[92m[c]children\u001b[0m, \u001b[92m[c]infants\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]RSV\u001b[0m, \u001b[92m[c]RSV\u001b[0m, \u001b[92m[c]mortality\u001b[0m, \u001b[91minfants\u001b[0m, \u001b[91mAML\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mAML\u001b[0m\n",
      "============================\n",
      "RESULT: However , \u001b[1m[\u001b[94mARG1 neonates , older individuals , and those with immune deficiencies ]\u001b[0m are prone to more frequent and more serious \u001b[1m[\u001b[94mARG2 CNS viral infections ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mHowever\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]immune\u001b[0m, \u001b[92m[c]individuals\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[92m[c]neonates\u001b[0m, \u001b[92m[c]deficiencies\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[94m[p]those\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infections\u001b[0m, \u001b[92m[c]viral\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]CNS\u001b[0m, \u001b[91mneonates\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mindividuals\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mand\u001b[0m\n",
      "============================\n",
      "RESULT: However , \u001b[1m[\u001b[94mARG1 immunocompromised individuals ]\u001b[0m , both children and adults , are prone to develop \u001b[1m[\u001b[94mARG2 severe illness ]\u001b[0m as a result of \u001b[1m[\u001b[94mARG1 HPIV infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91millness\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]individuals\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[92m[c]immunocompromised\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]illness\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]severe\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mHPIV\u001b[0m, \u001b[91mindividuals\u001b[0m, \u001b[91m,\u001b[0m\n",
      "============================\n",
      "RESULT: Due to the physiological changes in their immune and cardiopulmonary systems , \u001b[1m[\u001b[94mARG1 pregnant women ]\u001b[0m are more likely to develop \u001b[1m[\u001b[94mARG2 severe illness ]\u001b[0m after infection with \u001b[1m[\u001b[94mARG1 respiratory viruses ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91millness\u001b[0m, \u001b[92m[c]pregnant\u001b[0m, \u001b[92m[c]viruses\u001b[0m, \u001b[92m[c]women\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mafter\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mphysiological\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]illness\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mviruses\u001b[0m, \u001b[91mafter\u001b[0m, \u001b[92m[c]severe\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mpregnant\u001b[0m, \u001b[91mphysiological\u001b[0m\n",
      "============================\n",
      "RESULT: The patients with \u001b[1m[\u001b[94mARG1 rheumatic immune diseases ]\u001b[0m have immune dysfunction and are often on glucocorticoid and immunosuppressant therapy , which in turn predispose them to an \u001b[1m[\u001b[94mARG2 increased risk of contracting SARS-CoV-2 infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]diseases\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mdysfunction\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[92m[c]immune\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[94m[p]contracting\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]contracting\u001b[0m, \u001b[91mthem\u001b[0m, \u001b[92m[c]risk\u001b[0m, \u001b[91mdiseases\u001b[0m\n",
      "============================\n",
      "RESULT: Although most infected patients have mild to moderate symptoms or are even asymptomatic , \u001b[1m[\u001b[94mARG1 older patients or those with existing chronic diseases ]\u001b[0m are at greater risk of developing \u001b[1m[\u001b[94mARG2 serious complications such as pneumonia or multiple organ failures ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[92m[c]diseases\u001b[0m, \u001b[92m[c]patients\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[92m[c]chronic\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mmost\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[92m[c]complications\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]or\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]serious\u001b[0m, \u001b[91mdiseases\u001b[0m\n",
      "============================\n",
      "RESULT: Among patients , those with \u001b[1m[\u001b[94mARG1 cystic fibrosis ( CF ) , chronic obstructive pulmonary disease ( COPD ) , and on mechanical ventilation ]\u001b[0m are particularly prone to develop \u001b[1m[\u001b[94mARG2 pneumonia caused by PA infection ]\u001b[0m [ 6 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]CF\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]ventilation\u001b[0m, \u001b[94m[p]COPD\u001b[0m, \u001b[91mAmong\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]pneumonia\u001b[0m, \u001b[94m[p]by\u001b[0m, \u001b[91mdevelop\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[92m[c]PA\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mAmong\u001b[0m, \u001b[94m[p]caused\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Cancer patients ]\u001b[0m , particularly those \u001b[1m[\u001b[94mARG1 under anticancer treatment ]\u001b[0m , are potentially more susceptible for a \u001b[1m[\u001b[94mARG2 severe infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Cancer\u001b[0m, \u001b[92m[c]patients\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]treatment\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[92m[c]anticancer\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mpotentially\u001b[0m, \u001b[91mthose\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]severe\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mCancer\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mpotentially\u001b[0m, \u001b[91msusceptible\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Affected individuals are immunosuppressed ]\u001b[0m , and therefore , are more susceptible to \u001b[1m[\u001b[94mARG2 influenza , viral enteritis , and distemper ]\u001b[0m [ 1 , 26 ] .\n",
      "ARG1 PREDS: \u001b[94m[p]individuals\u001b[0m, \u001b[94m[p]are\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[94m[p]Affected\u001b[0m, \u001b[94m[p]are\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]immunosuppressed\u001b[0m, \u001b[91menteritis\u001b[0m, \u001b[91m26\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]influenza\u001b[0m, \u001b[91mindividuals\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mAffected\u001b[0m, \u001b[92m[c]enteritis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mare\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Preterm infants ]\u001b[0m , especially \u001b[1m[\u001b[94mARG1 very low birth weight infants ]\u001b[0m , have low immune function , which is the main risk group of \u001b[1m[\u001b[94mARG2 neonatal fungal infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[92m[c]infants\u001b[0m, \u001b[92m[c]Preterm\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mfungal\u001b[0m, \u001b[92m[c]infants\u001b[0m, \u001b[91mneonatal\u001b[0m, \u001b[91mlow\u001b[0m, \u001b[91mfunction\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]fungal\u001b[0m, \u001b[92m[c]neonatal\u001b[0m, \u001b[91minfants\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[91mPreterm\u001b[0m, \u001b[91minfants\u001b[0m, \u001b[91mrisk\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 cancer ]\u001b[0m are more susceptible to \u001b[1m[\u001b[94mARG2 the infection ]\u001b[0m owing to their immunocompromised state .\n",
      "ARG1 PREDS: \u001b[92m[c]cancer\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mstate\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mcancer\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91msusceptible\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mmore\u001b[0m\n",
      "============================\n",
      "RESULT: Individuals with \u001b[1m[\u001b[94mARG1 underlying medical conditions ]\u001b[0m are at increased risk of \u001b[1m[\u001b[94mARG2 pneumonia ]\u001b[0m , which may be due to viral extension to the lungs or bacterial superinfection .\n",
      "ARG1 PREDS: \u001b[91mpneumonia\u001b[0m, \u001b[92m[c]conditions\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]underlying\u001b[0m, \u001b[94m[p]medical\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mor\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91mviral\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91msuperinfection\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mbacterial\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mIndividuals\u001b[0m, \u001b[91mor\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 immunodeficiency due to human immunodeficiency virus ( HIV ) infection ]\u001b[0m are highly susceptible to \u001b[1m[\u001b[94mARG2 viral sepsis ]\u001b[0m depending on the stage of disease and access and response to the treatment ( 19 ) .\n",
      "ARG1 PREDS: \u001b[91mPatients\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[92m[c]immunodeficiency\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]HIV\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91msepsis\u001b[0m, \u001b[91mviral\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]sepsis\u001b[0m, \u001b[92m[c]viral\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mHIV\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Elderly patients ]\u001b[0m are also more prone to \u001b[1m[\u001b[94mARG2 RSV infections ]\u001b[0m due to their decreased immunologic response to the virus [ 13 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]patients\u001b[0m, \u001b[92m[c]Elderly\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mRSV\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mtheir\u001b[0m, \u001b[91mdecreased\u001b[0m, \u001b[91mdecreased\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infections\u001b[0m, \u001b[92m[c]RSV\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mdecreased\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mElderly\u001b[0m, \u001b[91mtheir\u001b[0m\n",
      "============================\n",
      "RESULT: Patients with \u001b[1m[\u001b[94mARG1 DS ]\u001b[0m are highly susceptible to \u001b[1m[\u001b[94mARG2 lower and higher respiratory tract infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]DS\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mhighly\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91msusceptible\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mare\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mDS\u001b[0m, \u001b[92m[c]tract\u001b[0m, \u001b[91msusceptible\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mhighly\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: However , while \u001b[1m[\u001b[94mARG1 tocilizumab ]\u001b[0m is a promising agent against COVID-19 , it is not an appropriate agent in \u001b[1m[\u001b[94mARG2 patients with active or latent tuberculosis , bacterial and fungal infections , multi-organ failure , and gastrointestinal perforation ]\u001b[0m [ 7 ] .\n",
      "ARG1 PREDS: \u001b[91mit\u001b[0m, \u001b[91magent\u001b[0m, \u001b[91magent\u001b[0m, \u001b[92m[c]tocilizumab\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mtuberculosis\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]tuberculosis\u001b[0m, \u001b[92m[c]patients\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91magainst\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[92m[c]active\u001b[0m, \u001b[91mit\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: There are cases of ADEM or even fulminant presentation such as AHL where \u001b[1m[\u001b[94mARG1 steroids alone ]\u001b[0m are not sufficient for \u001b[1m[\u001b[94mARG2 suppressing inflammation and improving clinical findings ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]steroids\u001b[0m, \u001b[94m[p]alone\u001b[0m, \u001b[91minflammation\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mThere\u001b[0m, \u001b[91mnot\u001b[0m, \u001b[91meven\u001b[0m, \u001b[91msufficient\u001b[0m, \u001b[91mor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]inflammation\u001b[0m, \u001b[92m[c]clinical\u001b[0m, \u001b[91msteroids\u001b[0m, \u001b[91mAHL\u001b[0m, \u001b[91mThere\u001b[0m, \u001b[92m[c]findings\u001b[0m, \u001b[91mor\u001b[0m, \u001b[91mpresentation\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mADEM\u001b[0m\n",
      "============================\n",
      "RESULT: Thus , \u001b[1m[\u001b[94mARG1 ribavirin ]\u001b[0m may not be useful for treating \u001b[1m[\u001b[94mARG2 SARS infections ]\u001b[0m because of its questionable efficacy and because of its known toxicity ( reviewed by van Vonderen et al. , 2003 ; Lai , 2005 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]ribavirin\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mtreating\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mThus\u001b[0m, \u001b[91mtreating\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91mmay\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]SARS\u001b[0m, \u001b[92m[c]infections\u001b[0m, \u001b[91mtreating\u001b[0m, \u001b[91mtreating\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mThus\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mefficacy\u001b[0m\n",
      "============================\n",
      "RESULT: In general , \u001b[1m[\u001b[94mARG1 steroid therapy ]\u001b[0m is not recommended in the clinical treatment of \u001b[1m[\u001b[94mARG2 SARS-CoV-2 ]\u001b[0m [ 103 ] .\n",
      "ARG1 PREDS: \u001b[94m[p]therapy\u001b[0m, \u001b[92m[c]steroid\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91m]\u001b[0m, \u001b[91mnot\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mof\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91msteroid\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91m[\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m\n",
      "============================\n",
      "RESULT: In fact , \u001b[1m[\u001b[94mARG1 steroids ]\u001b[0m are not recommended in \u001b[1m[\u001b[94mARG2 COVID-19 infection ]\u001b[0m outside of clinical trial because of potential increased risk of mechanical ventilation ( 10 ) .\n",
      "ARG1 PREDS: \u001b[94m[p]steroids\u001b[0m, \u001b[91mventilation\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mmechanical\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mtrial\u001b[0m, \u001b[91m10\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91msteroids\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mventilation\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mincreased\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG2 Patients with PCP ]\u001b[0m typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[1m[\u001b[94mARG1 corticosteroids ]\u001b[0m have failed to demonstrate benefit outside of the HIV population [ 62 , 63 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]corticosteroids\u001b[0m, \u001b[91mPatients\u001b[0m, \u001b[91mHIV\u001b[0m, \u001b[91mPCP\u001b[0m, \u001b[91mbenefit\u001b[0m, \u001b[91mrefractory\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhypoxemia\u001b[0m, \u001b[91mrefractory\u001b[0m, \u001b[91mdie\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]Patients\u001b[0m, \u001b[91mHIV\u001b[0m, \u001b[92m[c]PCP\u001b[0m, \u001b[91mpopulation\u001b[0m, \u001b[94m[p]with\u001b[0m, \u001b[91mrefractory\u001b[0m, \u001b[91mrefractory\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mhypoxemia\u001b[0m, \u001b[91mcorticosteroids\u001b[0m\n",
      "============================\n",
      "RESULT: In addition , \u001b[1m[\u001b[94mARG1 steroids ]\u001b[0m are not effective for the treatment of \u001b[1m[\u001b[94mARG2 lung injury or shock in adults ' SARS-CoV-2 infection ]\u001b[0m [ 11 ] .\n",
      "ARG1 PREDS: \u001b[94m[p]steroids\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91meffective\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mnot\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mshock\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]lung\u001b[0m, \u001b[92m[c]shock\u001b[0m, \u001b[94m[p]in\u001b[0m, \u001b[94m[p]'\u001b[0m, \u001b[91msteroids\u001b[0m, \u001b[94m[p]or\u001b[0m, \u001b[92m[c]injury\u001b[0m, \u001b[91m[\u001b[0m, \u001b[92m[c]adults\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Corticosteroids ]\u001b[0m in the treatment of \u001b[1m[\u001b[94mARG2 SARS-CoV-2 pneumonia ]\u001b[0m are not usually recommended ; they may delay virus clearance from the body [ 1 , 3 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]Corticosteroids\u001b[0m, \u001b[91mthey\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mclearance\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mbody\u001b[0m, \u001b[91mtreatment\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mvirus\u001b[0m, \u001b[94m[p]pneumonia\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mclearance\u001b[0m, \u001b[91mbody\u001b[0m, \u001b[91mCorticosteroids\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mthey\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: At present , there is no effective therapeutic agent against \u001b[1m[\u001b[94mARG2 CVB3 ]\u001b[0m , and only \u001b[1m[\u001b[94mARG1 ribavirin ]\u001b[0m is available for \u001b[1m[\u001b[94mARG2 CVB3 infection ]\u001b[0m despite its weak antiviral activity [ 93 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]ribavirin\u001b[0m, \u001b[91monly\u001b[0m, \u001b[91mantiviral\u001b[0m, \u001b[91magent\u001b[0m, \u001b[91mtherapeutic\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91monly\u001b[0m, \u001b[91m[\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[92m[c]CVB3\u001b[0m, \u001b[91mantiviral\u001b[0m, \u001b[92m[c]CVB3\u001b[0m, \u001b[91mtherapeutic\u001b[0m, \u001b[91magainst\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91magainst\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Drugs ]\u001b[0m currently licensed for the treatment of systemic \u001b[1m[\u001b[94mARG2 CMV infections ]\u001b[0m have limited therapeutic effectiveness due to dose-limiting toxicities , and prolonged therapy often results in resistance ( Biron , 2006 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]Drugs\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mtherapeutic\u001b[0m, \u001b[91mprolonged\u001b[0m, \u001b[91mresistance\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91mCMV\u001b[0m, \u001b[91mlicensed\u001b[0m, \u001b[91msystemic\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]CMV\u001b[0m, \u001b[92m[c]infections\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mDrugs\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mresistance\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mtherapeutic\u001b[0m, \u001b[91mhave\u001b[0m\n",
      "============================\n",
      "RESULT: Most of the \u001b[1m[\u001b[94mARG1 TCM agents ]\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[1m[\u001b[94mARG2 disease ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]agents\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91meffective\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mMost\u001b[0m, \u001b[92m[c]TCM\u001b[0m, \u001b[91mmodality\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[91magents\u001b[0m, \u001b[91mprogression\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91meffective\u001b[0m, \u001b[91mrapid\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mMost\u001b[0m\n",
      "============================\n",
      "RESULT: In addition , \u001b[1m[\u001b[94mARG1 antivirals such as NA inhibitors and M2 blockers ]\u001b[0m have limited efficacy in \u001b[1m[\u001b[94mARG2 severe cases of influenza infection ]\u001b[0m if not administered within 48 hours from symptoms onset and may select for resistance .\n",
      "ARG1 PREDS: \u001b[92m[c]antivirals\u001b[0m, \u001b[91m,\u001b[0m, \u001b[92m[c]blockers\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mresistance\u001b[0m, \u001b[91mhave\u001b[0m, \u001b[92m[c]NA\u001b[0m, \u001b[92m[c]inhibitors\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]influenza\u001b[0m, \u001b[92m[c]infection\u001b[0m, \u001b[91mantivirals\u001b[0m, \u001b[92m[c]severe\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mNA\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[91maddition\u001b[0m, \u001b[91m,\u001b[0m, \u001b[92m[c]cases\u001b[0m\n",
      "============================\n",
      "RESULT: The efficacy rate is also low in children , and the \u001b[1m[\u001b[94mARG1 treatment ]\u001b[0m is normally ineffective in \u001b[1m[\u001b[94mARG2 secondary ITP with underlying diseases , such as systemic lupus erythematosus ]\u001b[0m [ 25 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]treatment\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mrate\u001b[0m, \u001b[91mineffective\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mtreatment\u001b[0m, \u001b[91mchildren\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[94m[p]underlying\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]secondary\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mrate\u001b[0m\n",
      "============================\n",
      "RESULT: However , \u001b[1m[\u001b[94mARG1 the use of corticosteroids ]\u001b[0m in the treatment of \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m can cause host immune suppression and delay viral clearance .\n",
      "ARG1 PREDS: \u001b[92m[c]corticosteroids\u001b[0m, \u001b[94m[p]use\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mclearance\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mtreatment\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mhost\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91mclearance\u001b[0m, \u001b[91mcorticosteroids\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcause\u001b[0m\n",
      "============================\n",
      "RESULT: However , \u001b[1m[\u001b[94mARG1 the clinical use of interferon ]\u001b[0m to treat \u001b[1m[\u001b[94mARG2 dengue ]\u001b[0m is not common , possibly due to IFN-α side effects associated with its systemic activity .\n",
      "ARG1 PREDS: \u001b[92m[c]interferon\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mdengue\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[94m[p]use\u001b[0m, \u001b[94m[p]clinical\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mto\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]dengue\u001b[0m, \u001b[91mHowever\u001b[0m, \u001b[91minterferon\u001b[0m, \u001b[91mtreat\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91msystemic\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mactivity\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: Unfortunately , a consistent benefit has not been observed in all clinical trials and \u001b[1m[\u001b[94mARG1 ribavirin ]\u001b[0m is currently not considered to be a drug of choice for \u001b[1m[\u001b[94mARG2 influenza ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]ribavirin\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mdrug\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mtrials\u001b[0m, \u001b[91mbenefit\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91ma\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]influenza\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mtrials\u001b[0m, \u001b[91mall\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mbenefit\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mhas\u001b[0m\n",
      "============================\n",
      "RESULT: For \u001b[1m[\u001b[94mARG2 HSV encephalitis ]\u001b[0m , the efficacy of \u001b[1m[\u001b[94mARG1 aciclovir monotherapy ]\u001b[0m may be hampered by limited penetration of the drug in the central nervous system .\n",
      "ARG1 PREDS: \u001b[92m[c]aciclovir\u001b[0m, \u001b[91mdrug\u001b[0m, \u001b[92m[c]monotherapy\u001b[0m, \u001b[91mencephalitis\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcentral\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mpenetration\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]encephalitis\u001b[0m, \u001b[92m[c]HSV\u001b[0m, \u001b[91mFor\u001b[0m, \u001b[91mpenetration\u001b[0m, \u001b[91mdrug\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91mcentral\u001b[0m, \u001b[91mlimited\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91min\u001b[0m\n",
      "============================\n",
      "RESULT: Although , in a substantial cooperative study , \u001b[1m[\u001b[94mARG1 high-dose acyclovir ]\u001b[0m has had certain efficacy for preventing \u001b[1m[\u001b[94mARG2 CMV disease ]\u001b[0m ( 101 ) , its utility is limited in a setting where more potent anti-CMV agents ( e.g. , ganciclovir ) are used ( 102 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]acyclovir\u001b[0m, \u001b[91magents\u001b[0m, \u001b[91mganciclovir\u001b[0m, \u001b[91mits\u001b[0m, \u001b[94m[p]high-dose\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91mCMV\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m)\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]disease\u001b[0m, \u001b[92m[c]CMV\u001b[0m, \u001b[91msetting\u001b[0m, \u001b[91magents\u001b[0m, \u001b[91mpreventing\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91manti-CMV\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91mstudy\u001b[0m, \u001b[91mefficacy\u001b[0m\n",
      "============================\n",
      "RESULT: While \u001b[1m[\u001b[94mARG1 FAM ]\u001b[0m is standard therapy for \u001b[1m[\u001b[94mARG2 established BOS ]\u001b[0m , recent data argue strongly against using \u001b[1m[\u001b[94mARG1 azithromycin ]\u001b[0m as \u001b[1m[\u001b[94mARG2 prophylaxis against BOS ]\u001b[0m due to decreased survival due to a higher rate of hematologic relapse [ 83 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]FAM\u001b[0m, \u001b[92m[c]azithromycin\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91msurvival\u001b[0m, \u001b[91mprophylaxis\u001b[0m, \u001b[91mhematologic\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mBOS\u001b[0m, \u001b[91mBOS\u001b[0m\n",
      "ARG2 PREDS: \u001b[91msurvival\u001b[0m, \u001b[92m[c]BOS\u001b[0m, \u001b[92m[c]BOS\u001b[0m, \u001b[94m[p]established\u001b[0m, \u001b[91mhematologic\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mdata\u001b[0m, \u001b[92m[c]prophylaxis\u001b[0m, \u001b[91mrelapse\u001b[0m\n",
      "============================\n",
      "RESULT: Although a number of \u001b[1m[\u001b[94mARG1 antivirals ]\u001b[0m are available for \u001b[1m[\u001b[94mARG2 influenza infections ]\u001b[0m ( e.g. , \u001b[1m[\u001b[94mARG1 M2 and neuraminidase inhibitors ]\u001b[0m ) , these drugs have only modest efficacy and their use is further limited by resistance that is either preexisting or is rapidly induced during treatment ( 192 ) .\n",
      "ARG1 PREDS: \u001b[91mdrugs\u001b[0m, \u001b[91mof\u001b[0m, \u001b[92m[c]inhibitors\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[92m[c]antivirals\u001b[0m, \u001b[91minfluenza\u001b[0m, \u001b[91mthese\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91minfections\u001b[0m, \u001b[91muse\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]influenza\u001b[0m, \u001b[92m[c]infections\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mdrugs\u001b[0m, \u001b[91mresistance\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mantivirals\u001b[0m, \u001b[91mthese\u001b[0m, \u001b[91mefficacy\u001b[0m, \u001b[91mand\u001b[0m\n",
      "============================\n",
      "RESULT: Although \u001b[1m[\u001b[94mARG1 immunosuppression ]\u001b[0m is a mainstay of treatment for \u001b[1m[\u001b[94mARG2 autoimmunity ]\u001b[0m , \u001b[1m[\u001b[94mARG1 IPEX treatment ]\u001b[0m is frequently limited by insufficient response to therapy or side effects of immune suppression .\n",
      "ARG1 PREDS: \u001b[92m[c]treatment\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mAlthough\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[92m[c]IPEX\u001b[0m, \u001b[91mautoimmunity\u001b[0m, \u001b[91msuppression\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[92m[c]immunosuppression\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mimmune\u001b[0m, \u001b[92m[c]autoimmunity\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mIPEX\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91msuppression\u001b[0m, \u001b[91mor\u001b[0m\n",
      "============================\n",
      "RESULT: There has traditionally been no specific treatment for \u001b[1m[\u001b[94mARG2 CCHF ]\u001b[0m , though \u001b[1m[\u001b[94mARG1 ribavirin ]\u001b[0m has demonstrated both in vitro and in vivo activity [ 40 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]ribavirin\u001b[0m, \u001b[91mthough\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mactivity\u001b[0m, \u001b[91mthough\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mThere\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mspecific\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]CCHF\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mactivity\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mthough\u001b[0m, \u001b[91mspecific\u001b[0m, \u001b[91mand\u001b[0m\n",
      "============================\n",
      "RESULT: Although \u001b[1m[\u001b[94mARG1 biologic therapies ]\u001b[0m provide a valuable treatment option in \u001b[1m[\u001b[94mARG2 UC ]\u001b[0m , they are not clinically effective in all patients and are also associated with secondary loss of response .\n",
      "ARG1 PREDS: \u001b[92m[c]biologic\u001b[0m, \u001b[92m[c]therapies\u001b[0m, \u001b[91mthey\u001b[0m, \u001b[91mresponse\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mUC\u001b[0m, \u001b[91meffective\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mclinically\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]UC\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mresponse\u001b[0m, \u001b[91mbiologic\u001b[0m, \u001b[91mtreatment\u001b[0m, \u001b[91mtherapies\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mthey\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mare\u001b[0m\n",
      "============================\n",
      "RESULT: Currently , there is no vaccine to prevent \u001b[1m[\u001b[94mARG2 RSV ]\u001b[0m , and the only accepted therapy ( \u001b[1m[\u001b[94mARG1 ribavirin ]\u001b[0m ) is seldom used due to its teratogenicity , its limited antiviral effect , and its controversial clinical effectiveness ( 41 , 76 , 85 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]ribavirin\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mRSV\u001b[0m, \u001b[91mantiviral\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mvaccine\u001b[0m, \u001b[91mused\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]RSV\u001b[0m, \u001b[91mprevent\u001b[0m, \u001b[91mtherapy\u001b[0m, \u001b[91mantiviral\u001b[0m, \u001b[91mclinical\u001b[0m, \u001b[91mvaccine\u001b[0m, \u001b[91mCurrently\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mused\u001b[0m, \u001b[91m(\u001b[0m\n",
      "============================\n",
      "RESULT: Treatment with \u001b[1m[\u001b[94mARG1 M2 inhibitors ]\u001b[0m , such as \u001b[1m[\u001b[94mARG1 amantadine ]\u001b[0m , is generally not used in \u001b[1m[\u001b[94mARG2 transplant recipients ]\u001b[0m because of widespread resistance , the association with prolonged shedding of virus and increased adverse effects [ 6 , 30 ] .\n",
      "ARG1 PREDS: \u001b[91mTreatment\u001b[0m, \u001b[92m[c]inhibitors\u001b[0m, \u001b[92m[c]amantadine\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mtransplant\u001b[0m, \u001b[91mrecipients\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mused\u001b[0m, \u001b[91mshedding\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mvirus\u001b[0m, \u001b[92m[c]transplant\u001b[0m, \u001b[91mTreatment\u001b[0m, \u001b[92m[c]recipients\u001b[0m, \u001b[91mprolonged\u001b[0m, \u001b[91mshedding\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mresistance\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91min\u001b[0m\n",
      "============================\n",
      "RESULT: Nevertheless , there is currently no definitive benefit proven for \u001b[1m[\u001b[94mARG1 antiviral treatment ]\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[1m[\u001b[94mARG1 zanamivir ]\u001b[0m can induce bronchospasms in patients with \u001b[1m[\u001b[94mARG2 chronic respiratory disease ]\u001b[0m and asthma .\n",
      "ARG1 PREDS: \u001b[92m[c]zanamivir\u001b[0m, \u001b[92m[c]antiviral\u001b[0m, \u001b[92m[c]treatment\u001b[0m, \u001b[91mit\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mthere\u001b[0m, \u001b[91minduce\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91min\u001b[0m, \u001b[91masthma\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mtreatment\u001b[0m, \u001b[91mbronchospasms\u001b[0m, \u001b[91mantiviral\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91masthma\u001b[0m, \u001b[91minduce\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[92m[c]disease\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Acute kidney injury ]\u001b[0m is a possible manifestation in severe forms of \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m , conferring a high mortality 7 .\n",
      "ARG1 PREDS: \u001b[92m[c]injury\u001b[0m, \u001b[92m[c]kidney\u001b[0m, \u001b[92m[c]Acute\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91mmanifestation\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[91msevere\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mforms\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91minjury\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Coagulation dysfunction ]\u001b[0m is one of the major causes for death in patients with \u001b[1m[\u001b[94mARG2 severe COVID-19 ]\u001b[0m [ 4 ] .\n",
      "ARG1 PREDS: \u001b[91mdeath\u001b[0m, \u001b[92m[c]Coagulation\u001b[0m, \u001b[92m[c]dysfunction\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91msevere\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91min\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[91m]\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Coagulopathy ]\u001b[0m is one of the main complications occurring in hospitalized patients with severe \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[92m[c]Coagulopathy\u001b[0m, \u001b[91mhospitalized\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91moccurring\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mhospitalized\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Hypoxia ]\u001b[0m is the most common manifestation of patients with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m , especially in severely or critically ill patients .\n",
      "ARG1 PREDS: \u001b[92m[c]Hypoxia\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mmanifestation\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mseverely\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mHypoxia\u001b[0m, \u001b[91mmanifestation\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Early-onset pneumonia ]\u001b[0m is a common and severe complication that is related to aspiration in patients with \u001b[1m[\u001b[94mARG2 GBS ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91maspiration\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[92m[c]Early-onset\u001b[0m, \u001b[91mGBS\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91msevere\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mpneumonia\u001b[0m, \u001b[91min\u001b[0m, \u001b[91maspiration\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]GBS\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Barotrauma ]\u001b[0m is a common complication in patients with \u001b[1m[\u001b[94mARG2 SARS ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Barotrauma\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[92m[c]SARS\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mBarotrauma\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 COVID-19 infection ]\u001b[0m is associated with several \u001b[1m[\u001b[94mARG2 cardiac complications ]\u001b[0m with high rates of adverse outcomes .\n",
      "ARG1 PREDS: \u001b[92m[c]infection\u001b[0m, \u001b[91mcardiac\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91madverse\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[91moutcomes\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]cardiac\u001b[0m, \u001b[92m[c]complications\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[91mCOVID-19\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mhigh\u001b[0m, \u001b[91moutcomes\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 AKI ]\u001b[0m is one of the common complications with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m , and is associated with increased morbidity and mortality .\n",
      "ARG1 PREDS: \u001b[92m[c]AKI\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mincreased\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91mmorbidity\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mis\u001b[0m, \u001b[91mAKI\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m,\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mincreased\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Spontaneous pneumothorax ]\u001b[0m is a specific and potentially life-threatening complication in \u001b[1m[\u001b[94mARG2 SARS ]\u001b[0m patients .\n",
      "ARG1 PREDS: \u001b[92m[c]pneumothorax\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]Spontaneous\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[92m[c]Spontaneous\u001b[0m, \u001b[91ma\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[92m[c]SARS\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91min\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mSpontaneous\u001b[0m, \u001b[91mpneumothorax\u001b[0m, \u001b[91mSpontaneous\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG2 COVID-19 pneumonia ]\u001b[0m may lead to \u001b[1m[\u001b[94mARG1 acute respiratory distress syndrome and severe respiratory failure ]\u001b[0m ( 1 ) .\n",
      "ARG1 PREDS: \u001b[91mpneumonia\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[92m[c]failure\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[94m[p]severe\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mto\u001b[0m, \u001b[92m[c]syndrome\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91m)\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]pneumonia\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mand\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91m1\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mlead\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Pneumonia ]\u001b[0m is the most frequent and serious complication of \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m , due to excessive host immune response causing an acute respiratory distress syndrome .\n",
      "ARG1 PREDS: \u001b[92m[c]Pneumonia\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91man\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91msyndrome\u001b[0m, \u001b[91mresponse\u001b[0m, \u001b[91mexcessive\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mPneumonia\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mimmune\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91man\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Acute respiratory distress syndrome ]\u001b[0m developing in patients with \u001b[1m[\u001b[94mARG2 COVID-19 pneumonia ]\u001b[0m is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 infection [ 1 ] .\n",
      "ARG1 PREDS: \u001b[91mpneumonia\u001b[0m, \u001b[92m[c]syndrome\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mdeveloping\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[91mpatients\u001b[0m\n",
      "ARG2 PREDS: \u001b[91minfection\u001b[0m, \u001b[92m[c]pneumonia\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Pneumonia ]\u001b[0m is a life-threatening complication of \u001b[1m[\u001b[94mARG2 COVID-19 infection 10 ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Pneumonia\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mlife-threatening\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[91mPneumonia\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[94m[p]10\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 ARDS and shock ]\u001b[0m are common complications that can lead to death in \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m patients .\n",
      "ARG1 PREDS: \u001b[92m[c]shock\u001b[0m, \u001b[92m[c]ARDS\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mthat\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mshock\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[91mdeath\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Multiorgan injury ]\u001b[0m , which significantly increases mortality , is often evident in patients with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]injury\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mevident\u001b[0m, \u001b[91min\u001b[0m, \u001b[92m[c]Multiorgan\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minjury\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mevident\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Acute IH ]\u001b[0m is a significant complication of \u001b[1m[\u001b[94mARG2 high-dose IVIg infusion ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]IH\u001b[0m, \u001b[92m[c]Acute\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minfusion\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mIVIg\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91msignificant\u001b[0m, \u001b[91mhigh-dose\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]infusion\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mAcute\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[92m[c]IVIg\u001b[0m, \u001b[94m[p]high-dose\u001b[0m, \u001b[91mIH\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Multiorgan failure and disseminated intravascular coagulation ( DIC ) ]\u001b[0m are also frequently observed during \u001b[1m[\u001b[94mARG2 COVID-19 infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]DIC\u001b[0m, \u001b[92m[c]failure\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[91mare\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mduring\u001b[0m, \u001b[91mobserved\u001b[0m, \u001b[91malso\u001b[0m, \u001b[92m[c]coagulation\u001b[0m, \u001b[91mfrequently\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[91mduring\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mduring\u001b[0m, \u001b[91mobserved\u001b[0m, \u001b[91mduring\u001b[0m, \u001b[91mand\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91malso\u001b[0m, \u001b[91mfrequently\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Acute Respiratory Distress Syndrome ( ARDS ) ]\u001b[0m is one of the commonest complications developing in patients with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m [ 6 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]ARDS\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[92m[c]Syndrome\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mdeveloping\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91min\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcomplications\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mdeveloping\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Cardiac injury ]\u001b[0m is a common condition among the hospitalized patients with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]injury\u001b[0m, \u001b[92m[c]Cardiac\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mhospitalized\u001b[0m, \u001b[91mcondition\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mhospitalized\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91minjury\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mCardiac\u001b[0m, \u001b[91mcondition\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 DIC ]\u001b[0m is a severe complication in \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m patients and it has been related to poor prognosis and increased mortality ( 71.4 % of patient who die of COVID-19 ) ( 2 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]DIC\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mit\u001b[0m, \u001b[91msevere\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mprognosis\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mcomplication\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mpatient\u001b[0m, \u001b[91mDIC\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mit\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Thrombocytopenia ]\u001b[0m is one of the most common symptoms in patients with \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Thrombocytopenia\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mone\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91msymptoms\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mone\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 AKI ]\u001b[0m occurs frequently among patients with \u001b[1m[\u001b[94mARG2 Covid-19 disease ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[94m[p]AKI\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91moccurs\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mfrequently\u001b[0m, \u001b[91mamong\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mCovid-19\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]disease\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mAKI\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91moccurs\u001b[0m, \u001b[91mamong\u001b[0m, \u001b[92m[c]Covid-19\u001b[0m, \u001b[91mfrequently\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 AKI ]\u001b[0m occurs frequently among patients with \u001b[1m[\u001b[94mARG2 Covid-19 disease ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[94m[p]AKI\u001b[0m, \u001b[91mdisease\u001b[0m, \u001b[91moccurs\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mfrequently\u001b[0m, \u001b[91mamong\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mCovid-19\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]disease\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mAKI\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91moccurs\u001b[0m, \u001b[91mamong\u001b[0m, \u001b[92m[c]Covid-19\u001b[0m, \u001b[91mfrequently\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 HTN ]\u001b[0m is a comorbid condition which has been reported to be associated with increased mortality in patients with \u001b[1m[\u001b[94mARG2 COVID-19 infection ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mmortality\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91minfection\u001b[0m, \u001b[92m[c]HTN\u001b[0m, \u001b[91mcondition\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mcomorbid\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]infection\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mcondition\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 AKI ]\u001b[0m is a common consequence of \u001b[1m[\u001b[94mARG2 COVID-19 ]\u001b[0m , either due to ATN or hypotension .\n",
      "ARG1 PREDS: \u001b[92m[c]AKI\u001b[0m, \u001b[91mhypotension\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[91mATN\u001b[0m, \u001b[91mconsequence\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mor\u001b[0m, \u001b[91mto\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mis\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mAKI\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mhypotension\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mcommon\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mor\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Acute respiratory distress ]\u001b[0m is one of the major causes of mortality associated with \u001b[1m[\u001b[94mARG2 COVID-19 disease ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mdisease\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[92m[c]Acute\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]distress\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mone\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]disease\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mmortality\u001b[0m, \u001b[91mwith\u001b[0m, \u001b[91mAcute\u001b[0m, \u001b[91massociated\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mrespiratory\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG2 RSV-induced ]\u001b[0m \u001b[1m[\u001b[94mARG1 ARDS ]\u001b[0m is very uncommon but can be lethal in immunocompetent patients .\n",
      "ARG1 PREDS: \u001b[92m[c]ARDS\u001b[0m, \u001b[91mRSV-induced\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mRSV-induced\u001b[0m, \u001b[91mlethal\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mcan\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mpatients\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]RSV-induced\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mARDS\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mbut\u001b[0m, \u001b[91mlethal\u001b[0m, \u001b[92m[c]RSV-induced\u001b[0m, \u001b[91mimmunocompetent\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: If we aim to control the failure rate of \u001b[1m[\u001b[94mARG1 quarantine ]\u001b[0m to be below 1 % with 95 % confidence , then the quarantine period must be \u001b[1m[\u001b[94mARG2 at least 22 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[91mquarantine\u001b[0m, \u001b[92m[c]quarantine\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mfailure\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]22\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mfailure\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mquarantine\u001b[0m, \u001b[91mmust\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: In general , the \u001b[1m[\u001b[94mARG1 duration of the quarantine period ]\u001b[0m should be \u001b[1m[\u001b[94mARG2 21 to 30 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[94m[p]duration\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mgeneral\u001b[0m, \u001b[91mdays\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]30\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[92m[c]21\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mshould\u001b[0m, \u001b[91mgeneral\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: Although for extreme cases , the \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m should be extended \u001b[1m[\u001b[94mARG2 up to three weeks ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mweeks\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mthree\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]three\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[94m[p]to\u001b[0m, \u001b[91mextreme\u001b[0m, \u001b[94m[p]up\u001b[0m, \u001b[91mAlthough\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mbe\u001b[0m\n",
      "============================\n",
      "RESULT: At the beginning and the end of a SARS epidemic , to control the epidemic completely , we recommend \u001b[1m[\u001b[94mARG2 a period of 22 days ]\u001b[0m for \u001b[1m[\u001b[94mARG1 quarantine ]\u001b[0m , which would capture 99 percent of all probable SARS cases with a probability of 0.9 .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mepidemic\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[91mcontrol\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[91mepidemic\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]22\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[94m[p]period\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[94m[p]a\u001b[0m, \u001b[91mAt\u001b[0m, \u001b[91mcontrol\u001b[0m, \u001b[91mwe\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mwhich\u001b[0m\n",
      "============================\n",
      "RESULT: Based on the 95th percentile estimate of the incubation period , we recommend that the \u001b[1m[\u001b[94mARG1 length of quarantine ]\u001b[0m should be \u001b[1m[\u001b[94mARG2 at least 14 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mestimate\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mwe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]14\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mwe\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mlength\u001b[0m, \u001b[91mon\u001b[0m, \u001b[91mbe\u001b[0m\n",
      "============================\n",
      "RESULT: As such , the \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m should be extended \u001b[1m[\u001b[94mARG2 up to three weeks ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mweeks\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mextended\u001b[0m, \u001b[91mthree\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]three\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[94m[p]to\u001b[0m, \u001b[94m[p]up\u001b[0m, \u001b[91mextended\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mshould\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: For example , if the rate of transmission is reduced by 10 % , \u001b[1m[\u001b[94mARG1 the quarantine ]\u001b[0m from symptom onset needs to be implemented within \u001b[1m[\u001b[94mARG2 32.37 h+. ]\u001b[0m\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91msymptom\u001b[0m, \u001b[91mtransmission\u001b[0m, \u001b[91monset\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mrate\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mwithin\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91msymptom\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91mwithin\u001b[0m, \u001b[91mimplemented\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mexample\u001b[0m, \u001b[91mtransmission\u001b[0m, \u001b[91mreduced\u001b[0m\n",
      "============================\n",
      "RESULT: If testing is not done , the \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m \u001b[1m[\u001b[94mARG2 should at least exceed the incubation and shedding period ]\u001b[0m of the diseases of concern .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mtesting\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mshedding\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mperiod\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mtesting\u001b[0m, \u001b[94m[p]should\u001b[0m, \u001b[91mof\u001b[0m, \u001b[94m[p]exceed\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: Therefore , the \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m should be \u001b[1m[\u001b[94mARG2 around 2 weeks ]\u001b[0m after a close contact with a person with symptoms .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mcontact\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mperson\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mclose\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]2\u001b[0m, \u001b[91mafter\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[94m[p]around\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mTherefore\u001b[0m, \u001b[91mclose\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: As per the CDC guidelines , \u001b[1m[\u001b[94mARG2 14 days ]\u001b[0m should be \u001b[1m[\u001b[94mARG1 the period of quarantine ]\u001b[0m ( Science Daily website ) .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91m(\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mAs\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]14\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mshould\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: The \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m is typically \u001b[1m[\u001b[94mARG2 30 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mdays\u001b[0m, \u001b[91m30\u001b[0m, \u001b[91mtypically\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]30\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mtypically\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mquarantine\u001b[0m, \u001b[91mThe\u001b[0m\n",
      "============================\n",
      "RESULT: Because a longer and more volatile incubation period has been observed in travelers , the \u001b[1m[\u001b[94mARG1 duration of quarantine ]\u001b[0m should be extended to \u001b[1m[\u001b[94mARG2 3 weeks ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mtravelers\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[94m[p]of\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]3\u001b[0m, \u001b[91mof\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mtravelers\u001b[0m, \u001b[91mextended\u001b[0m\n",
      "============================\n",
      "RESULT: The time for which a patient can infect others varies between 7 and 14 days for moderate cases according to [ 3 ] , and this is why \u001b[1m[\u001b[94mARG1 quarantine ]\u001b[0m should last \u001b[1m[\u001b[94mARG2 at least two weeks ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mwhy\u001b[0m, \u001b[91mwhy\u001b[0m, \u001b[91mtime\u001b[0m, \u001b[91mpatient\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91minfect\u001b[0m, \u001b[91mlast\u001b[0m, \u001b[91mcan\u001b[0m\n",
      "ARG2 PREDS: \u001b[91m14\u001b[0m, \u001b[91mdays\u001b[0m, \u001b[91mtime\u001b[0m, \u001b[91m7\u001b[0m, \u001b[92m[c]two\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mmoderate\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "============================\n",
      "RESULT: Therefore , we suggest that the appropriate \u001b[1m[\u001b[94mARG1 duration of quarantine ]\u001b[0m is \u001b[1m[\u001b[94mARG2 4 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]duration\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mappropriate\u001b[0m, \u001b[91mwe\u001b[0m, \u001b[91mdays\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]4\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mTherefore\u001b[0m, \u001b[91mwe\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mappropriate\u001b[0m\n",
      "============================\n",
      "RESULT: A \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m of \u001b[1m[\u001b[94mARG2 at least 15 days ]\u001b[0m should allow adequate time for the return and evaluation of test data .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mA\u001b[0m, \u001b[92m[c]period\u001b[0m, \u001b[91mtest\u001b[0m, \u001b[91mdata\u001b[0m, \u001b[91mA\u001b[0m, \u001b[91mA\u001b[0m, \u001b[91mtime\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]15\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mA\u001b[0m, \u001b[91madequate\u001b[0m, \u001b[91mshould\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mtest\u001b[0m, \u001b[91mdata\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mtime\u001b[0m\n",
      "============================\n",
      "RESULT: At the moment , the WHO-established \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m is \u001b[1m[\u001b[94mARG2 14 days ]\u001b[0m based on previous reports which had studied small sizes of hospitalized cases ( 10 and ~100 , respectively ) , however , over 80 % of adult- and 95 % of child-cases were not necessary to stay in hospitals , and therefore , had not been hospitalized .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mWHO-established\u001b[0m, \u001b[94m[p]period\u001b[0m, \u001b[91mWHO-established\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mcases\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mhospitalized\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]14\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91m~100\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mnot\u001b[0m, \u001b[91mwere\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Quarantine duration ]\u001b[0m depends on national regulations but should be \u001b[1m[\u001b[94mARG2 a minimum of 30 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]Quarantine\u001b[0m, \u001b[94m[p]duration\u001b[0m, \u001b[91mnational\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mdays\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91m30\u001b[0m, \u001b[91mbut\u001b[0m, \u001b[91mon\u001b[0m, \u001b[91mminimum\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]30\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91mnational\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mQuarantine\u001b[0m, \u001b[94m[p]minimum\u001b[0m, \u001b[91mregulations\u001b[0m, \u001b[91mon\u001b[0m, \u001b[94m[p]a\u001b[0m\n",
      "============================\n",
      "RESULT: We recommend that the \u001b[1m[\u001b[94mARG1 duration of quarantine ]\u001b[0m should be \u001b[1m[\u001b[94mARG2 at least 14 days ]\u001b[0m on the basis of the 95th percentile estimate of the incubation period ( 10 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[94m[p]duration\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mWe\u001b[0m, \u001b[91mestimate\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]14\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91m10\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mWe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mbe\u001b[0m\n",
      "============================\n",
      "RESULT: A minimum \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m of \u001b[1m[\u001b[94mARG2 60 to 90 days ]\u001b[0m is recommended in a building that is separate from the main facility .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]period\u001b[0m, \u001b[91mminimum\u001b[0m, \u001b[91mminimum\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mmain\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mfacility\u001b[0m, \u001b[91mbuilding\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]90\u001b[0m, \u001b[92m[c]60\u001b[0m, \u001b[91mis\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mA\u001b[0m, \u001b[91mrecommended\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mminimum\u001b[0m, \u001b[91mmain\u001b[0m, \u001b[91min\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 The quarantine period ]\u001b[0m , which starts when the most recently received animals are placed into a quarantine , \u001b[1m[\u001b[94mARG2 should not be less than several weeks ]\u001b[0m , to allow time for seroconversion to infectious agents acquired in transit .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mquarantine\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[94m[p]period\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mseroconversion\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mare\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]several\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91manimals\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91minfectious\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91ma\u001b[0m\n",
      "============================\n",
      "RESULT: The incubation period of SARS was described as \u001b[1m[\u001b[94mARG2 20 days ]\u001b[0m , meaning a \u001b[1m[\u001b[94mARG1 quarantine officer ]\u001b[0m could detain a person suspected of having SARS up to that period of time .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[91mtime\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mperson\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mSARS\u001b[0m, \u001b[94m[p]officer\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]20\u001b[0m, \u001b[92m[c]days\u001b[0m, \u001b[91mwas\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mas\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mtime\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: Upon the finding of longer and more volatile incubation period in travelers , the \u001b[1m[\u001b[94mARG1 duration of quarantine ]\u001b[0m should be extended to \u001b[1m[\u001b[94mARG2 three weeks ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mbe\u001b[0m, \u001b[91mtravelers\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[91min\u001b[0m, \u001b[91min\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]three\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mduration\u001b[0m, \u001b[91mto\u001b[0m, \u001b[92m[c]weeks\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mtravelers\u001b[0m, \u001b[91mbe\u001b[0m\n",
      "============================\n",
      "RESULT: If there is a potential exposure risk during the process , a \u001b[1m[\u001b[94mARG2 14-day ]\u001b[0m \u001b[1m[\u001b[94mARG1 quarantine ]\u001b[0m is required .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mprocess\u001b[0m, \u001b[91m14-day\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m14-day\u001b[0m, \u001b[91mexposure\u001b[0m, \u001b[91mrequired\u001b[0m, \u001b[91m14-day\u001b[0m, \u001b[91mrisk\u001b[0m, \u001b[91ma\u001b[0m\n",
      "ARG2 PREDS: \u001b[91ma\u001b[0m, \u001b[92m[c]14-day\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mrequired\u001b[0m, \u001b[91mprocess\u001b[0m, \u001b[91mduring\u001b[0m, \u001b[91mrisk\u001b[0m, \u001b[91mthere\u001b[0m\n",
      "============================\n",
      "RESULT: We recommend a \u001b[1m[\u001b[94mARG2 22-day ]\u001b[0m \u001b[1m[\u001b[94mARG1 quarantine period ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91m22-day\u001b[0m, \u001b[94m[p]period\u001b[0m, \u001b[91m22-day\u001b[0m, \u001b[91m22-day\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mWe\u001b[0m, \u001b[91mrecommend\u001b[0m, \u001b[91ma\u001b[0m\n",
      "ARG2 PREDS: \u001b[91ma\u001b[0m, \u001b[92m[c]22-day\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mWe\u001b[0m, \u001b[92m[c]22-day\u001b[0m, \u001b[91mrecommend\u001b[0m, \u001b[91mquarantine\u001b[0m, \u001b[92m[c]22-day\u001b[0m\n",
      "============================\n",
      "RESULT: From official reports , the \u001b[1m[\u001b[94mARG1 quarantine buffer ]\u001b[0m in January is around \u001b[1m[\u001b[94mARG2 15 d ]\u001b[0m and around 6 d on February 8 .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mofficial\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]buffer\u001b[0m, \u001b[91mreports\u001b[0m, \u001b[91md\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]15\u001b[0m, \u001b[91m6\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mofficial\u001b[0m, \u001b[91m8\u001b[0m, \u001b[92m[c]d\u001b[0m, \u001b[91mFrom\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mreports\u001b[0m\n",
      "============================\n",
      "RESULT: The incubation period alone suggests that 95 % effectiveness in preventing the release of symptomatic infected individuals is achieved by \u001b[1m[\u001b[94mARG1 quarantine ]\u001b[0m of \u001b[1m[\u001b[94mARG2 2.73 days ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]quarantine\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91minfected\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91msymptomatic\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]days\u001b[0m, \u001b[92m[c]2.73\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mperiod\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mincubation\u001b[0m, \u001b[91msymptomatic\u001b[0m, \u001b[91msuggests\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m targets human angiotensin-converting enzyme 2 ( hACE2 ) and infects \u001b[1m[\u001b[94mARG2 +intrapulmonary epithelial cells+ ]\u001b[0m more than cells of the upper airways [ 13 , 14 ] .\n",
      "ARG1 PREDS: \u001b[91m2\u001b[0m, \u001b[91mhACE2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mmore\u001b[0m, \u001b[91mcells+\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mhuman\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]epithelial\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mairways\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91m[\u001b[0m, \u001b[92m[c]+intrapulmonary\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[92m[c]cells+\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 ACE2 + cells ]\u001b[0m in the oral mucosa and lungs , including \u001b[1m[\u001b[94mARG2 ACE-2 cells ]\u001b[0m in the alveoli [ 97 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91m[\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91moral\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[91moral\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91mmucosa\u001b[0m, \u001b[91min\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: Like other viruses , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 lung alveolar epithelial cells ]\u001b[0m using receptor-mediated endocytosis via the angiotensin-converting enzyme II ( ACE2 ) as an entry receptor [ 4 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mviruses\u001b[0m, \u001b[91man\u001b[0m, \u001b[91m[\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]lung\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mviruses\u001b[0m, \u001b[91mendocytosis\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91musing\u001b[0m, \u001b[91m[\u001b[0m\n",
      "============================\n",
      "RESULT: Initially , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 cells in the respiratory system ]\u001b[0m and causes inflammation and cell death .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mInitially\u001b[0m, \u001b[91minflammation\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91m,\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91minflammation\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[92m[c]system\u001b[0m, \u001b[94m[p]in\u001b[0m, \u001b[91mInitially\u001b[0m, \u001b[91mcauses\u001b[0m, \u001b[91mand\u001b[0m, \u001b[94m[p]the\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 The SARA-CoV-2 ]\u001b[0m primarily invades \u001b[1m[\u001b[94mARG2 alveolar epithelial cells ]\u001b[0m and interacts with ACE2 , leading to respiratory symptoms in patients [ 33 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARA-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mprimarily\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[94m[p]The\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91m[\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[91mpatients\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mprimarily\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: In the lungs , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 type I and type II alveolar epithelial cells ]\u001b[0m , as well as \u001b[1m[\u001b[94mARG2 alveolar macrophages ]\u001b[0m that are among the first producers of pro-inflammatory cytokines .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mcytokines\u001b[0m, \u001b[91mare\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m binds to the ACE2 receptor on \u001b[1m[\u001b[94mARG2 ciliated bronchial epithelial cells ]\u001b[0m to gain entry into these cells for viral replication and dissemination in the airway [ 6 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mairway\u001b[0m, \u001b[91m6\u001b[0m, \u001b[91mbronchial\u001b[0m, \u001b[91mbinds\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mand\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[91mairway\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[92m[c]bronchial\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mthese\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 ACE2positive cells ]\u001b[0m in the oral mucosa and lungs , including \u001b[1m[\u001b[94mARG2 ACE2 + AT2 cells ]\u001b[0m in the alveoli .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mAT2\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mincluding\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mcells\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[91moral\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mmucosa\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mincluding\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m enters \u001b[1m[\u001b[94mARG2 host cells ]\u001b[0m by a mechanism involving the interaction between its spike ( S ) protein and human angiotensin-converting enzyme 2 ( ACE2 ) expressed on host cells in the lung [ 5 ] .\n",
      "ARG1 PREDS: \u001b[91m2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mprotein\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91min\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]host\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91mits\u001b[0m, \u001b[91mmechanism\u001b[0m, \u001b[91min\u001b[0m\n",
      "============================\n",
      "RESULT: Research has demonstrated that \u001b[1m[\u001b[94mARG1 COVID-19 ]\u001b[0m is caused by the severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) , which enters \u001b[1m[\u001b[94mARG2 the cells ]\u001b[0m by binding to the angiotensin-converting enzyme 2 ( ACE2 ) receptor .\n",
      "ARG1 PREDS: \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mthat\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]the\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mResearch\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mthat\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m invades target cells via its spike proteins , which bind to angiotensin-converting enzyme (ACE)-2 receptors that are widely distributed in \u001b[1m[\u001b[94mARG2 many types of human cells , including the alveolar type II cells in the lungs ]\u001b[0m [ 71 , 72 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m(ACE)-2\u001b[0m, \u001b[91mproteins\u001b[0m, \u001b[91mits\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mare\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mspike\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mcells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[91mtarget\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[94m[p]lungs\u001b[0m, \u001b[91mproteins\u001b[0m, \u001b[91mits\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[94m[p]the\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 human epithelial cells ]\u001b[0m through the host cell receptor angiotensin-converting enzyme II ( ACE2 ) , which is expressed on cells lining the lungs , oral buccal and gingiva ( 19 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91m19\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mepithelial\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91minfects\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mlungs\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91moral\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m can infect \u001b[1m[\u001b[94mARG2 cells ]\u001b[0m via the angiotensin-converting enzyme 2 ( ACE2 ) receptor which is ubiquitous but largely expressed in \u001b[1m[\u001b[94mARG2 endothelial cells ]\u001b[0m [ 10 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91minfect\u001b[0m, \u001b[91mendothelial\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mis\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]endothelial\u001b[0m, \u001b[91mcan\u001b[0m, \u001b[91minfect\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91min\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: Similar to SARS-CoV , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m exploits angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to invade cells , notably \u001b[1m[\u001b[94mARG2 type II alveolar epithelial cells ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mexploits\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mcells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91minvade\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mas\u001b[0m\n",
      "============================\n",
      "RESULT: The \u001b[1m[\u001b[94mARG1 SARS-Cov-2 ]\u001b[0m first predominantly infects lower airways and binds to ACE2 on \u001b[1m[\u001b[94mARG2 alveolar epithelial cells ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-Cov-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mfirst\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mpredominantly\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91mlower\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mairways\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mlower\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91mpredominantly\u001b[0m, \u001b[91mon\u001b[0m\n",
      "============================\n",
      "RESULT: Like a related coronavirus that emerged in 2003 , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m enters \u001b[1m[\u001b[94mARG2 human cells ]\u001b[0m by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( ACE2 ) [ 14 , 15 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mrelated\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mextracellular\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mrelated\u001b[0m, \u001b[91mbinding\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mrelated\u001b[0m\n",
      "============================\n",
      "RESULT: The primary target of \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m is the \u001b[1m[\u001b[94mARG2 upper respiratory mucosa ]\u001b[0m , and angiotensin-converting enzyme 2 ( ACE2 ) acts as a functional receptor for the viral spikes and eventually viral entry into host cells .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mspikes\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mviral\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mcells\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mtarget\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mprimary\u001b[0m, \u001b[92m[c]upper\u001b[0m\n",
      "============================\n",
      "RESULT: Studies have shown that \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m infects the \u001b[1m[\u001b[94mARG2 GI tract ]\u001b[0m via its viral receptor angiotensin converting enzyme II , which is expressed on \u001b[1m[\u001b[94mARG2 enterocytes of the ileum and colon ]\u001b[0m .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mStudies\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[92m[c]SARS-CoV-2\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]tract\u001b[0m, \u001b[92m[c]GI\u001b[0m, \u001b[91mStudies\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mon\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mits\u001b[0m, \u001b[94m[p]and\u001b[0m\n",
      "============================\n",
      "RESULT: Presumably , \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m infects \u001b[1m[\u001b[94mARG2 cells ]\u001b[0m through the S protein , which binds to cell surface receptor-angiotensin-converting enzyme 2 [ 4 ] .\n",
      "ARG1 PREDS: \u001b[91m2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mS\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91m,\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91minfects\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91minfects\u001b[0m, \u001b[91msurface\u001b[0m, \u001b[91msurface\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mPresumably\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m enters \u001b[1m[\u001b[94mARG2 respiratory epithelial cells ]\u001b[0m by attaching to angiotensin converting enzyme-2 ( ACE-2 ) via S-protein ; ACE-2 is also a receptor for SARS-CoV-1 [ 27 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-1\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91menzyme-2\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]respiratory\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91menters\u001b[0m, \u001b[91m;\u001b[0m, \u001b[91mSARS-CoV-1\u001b[0m\n",
      "============================\n",
      "RESULT: Like other coronaviruses , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect \u001b[1m[\u001b[94mARG2 different host cells ]\u001b[0m , and likely disrupts the renin-angiotensin-aldosterone system ( RAAS ) homeostasis .\n",
      "ARG1 PREDS: \u001b[94m[p]SARS-CoV-2\u001b[0m, \u001b[91mhACE2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mit\u001b[0m, \u001b[91mlikely\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91m,\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]host\u001b[0m, \u001b[92m[c]different\u001b[0m, \u001b[91mcellular\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mit\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mhomeostasis\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: Like a related coronavirus that emerged in 2003 ( Li et al. , 2003 ) , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m enters \u001b[1m[\u001b[94mARG2 human cells ]\u001b[0m by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( ACE2 ) ( Hoffmann et al. , 2020 ; Zhou et al. , 2020 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91m)\u001b[0m, \u001b[91mrelated\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[91mby\u001b[0m, \u001b[91mrelated\u001b[0m, \u001b[91mextracellular\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mrelated\u001b[0m, \u001b[91mLike\u001b[0m, \u001b[91mbinding\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m predominantly invades \u001b[1m[\u001b[94mARG2 alveolar epithelial cells ]\u001b[0m by binding to the ACE-2 receptor and then replicates within cells .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91mpredominantly\u001b[0m, \u001b[91mthen\u001b[0m, \u001b[91mreplicates\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mepithelial\u001b[0m, \u001b[91mpredominantly\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mcells\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mpredominantly\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mwithin\u001b[0m, \u001b[91mthen\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mby\u001b[0m\n",
      "============================\n",
      "RESULT: In \u001b[1m[\u001b[94mARG2 pulmonary tissue ]\u001b[0m , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host ’s cells [ 2 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mtissue\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mpulmonary\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mcells\u001b[0m, \u001b[92m[c]tissue\u001b[0m, \u001b[92m[c]pulmonary\u001b[0m, \u001b[91mIn\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91m’s\u001b[0m, \u001b[91mmembrane\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91menter\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m is considered a lower respiratory tract pathogen that gains access to the body by binding to the angiotensin-converting enzyme 2 ( ACE-2 ) on the surface of \u001b[1m[\u001b[94mARG2 alveolar epithelial type II cells ]\u001b[0m ( 2 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mpathogen\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91malveolar\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mbody\u001b[0m, \u001b[92m[c]alveolar\u001b[0m, \u001b[92m[c]cells\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91maccess\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m binds to the ACE2 receptor on \u001b[1m[\u001b[94mARG2 ciliated bronchial epithelial cells ]\u001b[0m to gain entry into these cells for viral replication and dissemination in the airway and systemically .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mbinds\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mbronchial\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]cells\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mthese\u001b[0m, \u001b[92m[c]epithelial\u001b[0m, \u001b[92m[c]bronchial\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[91mairway\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mentry\u001b[0m\n",
      "============================\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG2 Human angiotensin-converting enzyme 2 ( ACE2 ) ]\u001b[0m is a functional receptor hijacked by \u001b[1m[\u001b[94mARG1  SARS-CoV-2 ]\u001b[0m for cell entry , similar to SARS-CoV [ 8 , 16 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91m[\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[94m[p]2\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[94m[p]Human\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mis\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[92m[c]angiotensin-converting\u001b[0m\n",
      "============================\n",
      "RESULT: Molecularly , like SARS-CoV , the \u001b[1m[\u001b[94mARG1  SARS-CoV-2 virus ]\u001b[0m likely uses \u001b[1m[\u001b[94mARG2 ACE-2 ]\u001b[0m as entry receptor , which is highly expressed in the lung and gastrointestinal tract [ 10 ] [ 11 ] [ 12 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[92m[c]virus\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mlikely\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mentry\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE-2\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91muses\u001b[0m, \u001b[91muses\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mas\u001b[0m, \u001b[91mlung\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m enters respiratory epithelial cells by attaching to \u001b[1m[\u001b[94mARG2 angiotensin converting enzyme-2 ( ACE-2 ) ]\u001b[0m via S-protein ; \u001b[1m[\u001b[94mARG2 ACE-2 ]\u001b[0m is also a receptor for SARS-CoV-1 [ 27 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-1\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91menzyme-2\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91mfor\u001b[0m\n",
      "ARG2 PREDS: \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91mepithelial\u001b[0m, \u001b[92m[c]ACE-2\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[92m[c]angiotensin\u001b[0m, \u001b[92m[c]enzyme-2\u001b[0m, \u001b[91mrespiratory\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91m;\u001b[0m\n",
      "============================\n",
      "RESULT: With regard to \u001b[1m[\u001b[94mARG1  COVID-19 ]\u001b[0m , it is known that the \u001b[1m[\u001b[94mARG2 angiotensin-converting enzyme 2 ( ACE2 ) ACE2 ]\u001b[0m provides the cell membrane receptor entry point for SARS-CoV-2 .\n",
      "ARG1 PREDS: \u001b[91mSARS-CoV-2\u001b[0m, \u001b[92m[c]COVID-19\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mfor\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[94m[p]\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[92m[c]ACE2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mmembrane\u001b[0m, \u001b[92m[c]2\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[94m[p])\u001b[0m\n",
      "============================\n",
      "RESULT: It is now known that \u001b[1m[\u001b[94mARG1  SARS-CoV-2 ]\u001b[0m utilizes the same receptor of SARS-CoV , which is \u001b[1m[\u001b[94mARG2 angiotensin converting enzyme II ( ACE2 ) ]\u001b[0m for viral entry into the host cells [ 5 , 40 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mII\u001b[0m, \u001b[91msame\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mreceptor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]angiotensin\u001b[0m, \u001b[92m[c]II\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mviral\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91msame\u001b[0m, \u001b[91mhost\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 Both SARS-CoV and SARS-CoV-2 ]\u001b[0m infect human respiratory epithelial cells through the interaction of \u001b[1m[\u001b[94mARG2 spike protein with human ACE2 ]\u001b[0m , and only cells expressing ACE2 can be infected with SARS-CoV-2 in vitro [ 25 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[94m[p]Both\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mprotein\u001b[0m, \u001b[94m[p]and\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91mwith\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[91mexpressing\u001b[0m, \u001b[92m[c]protein\u001b[0m, \u001b[92m[c]human\u001b[0m, \u001b[91mBoth\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mepithelial\u001b[0m\n",
      "============================\n",
      "RESULT: Like a related coronavirus that emerged in 2003 ( Li et al. , 2003 ) , \u001b[1m[\u001b[94mARG1  SARS-CoV-2 ]\u001b[0m enters human cells by binding to the \u001b[1m[\u001b[94mARG2 extracellular domain of Angiotensin Converting Enzyme 2 ( ACE2 ) ]\u001b[0m ( Hoffmann et al. , 2020 ; Zhou et al. , 2020 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91mrelated\u001b[0m, \u001b[94m[p]\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91m)\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]2\u001b[0m, \u001b[92m[c]Enzyme\u001b[0m, \u001b[92m[c]Angiotensin\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[94m[p]of\u001b[0m, \u001b[92m[c]extracellular\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[94m[p])\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[1m[\u001b[94mARG2 ACE2 receptor ]\u001b[0m to establish host uptake [ 2 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91muptake\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91muptake\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mestablish\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m seems to use the same cell entry receptor , \u001b[1m[\u001b[94mARG2 ACE2 ]\u001b[0m , as the SARS-CoV because ACE2 shows binding to RBD of both SARS-CoV and SARS-CoV-2 [ 11 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mboth\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mseems\u001b[0m, \u001b[91mof\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mbecause\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mof\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m exploits the \u001b[1m[\u001b[94mARG2 ACE-2 receptor ]\u001b[0m , the same receptor as SARS , in the human lower respiratory tract for entry into lung cells [ 41 , 42 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE-2\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mhuman\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mexploits\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE-2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91m[\u001b[0m\n",
      "============================\n",
      "RESULT: Similar to severe acute respiratory syndrome-associated coronavirus ( SARS-CoV ) 16 , 17 , the \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m employs \u001b[1m[\u001b[94mARG2 angiotensin-converting enzyme-2 ( ACE2 ) ]\u001b[0m as a receptor for cellular entry .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91menzyme-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mcellular\u001b[0m, \u001b[91mreceptor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91memploys\u001b[0m, \u001b[92m[c]enzyme-2\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[92m[c]angiotensin-converting\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mcellular\u001b[0m\n",
      "============================\n",
      "RESULT: Like SARS-CoV , \u001b[1m[\u001b[94mARG1 2019-nCoV ]\u001b[0m may use \u001b[1m[\u001b[94mARG2 angiotensin-converting enzyme 2 ( ACE2 ) ]\u001b[0m as a potential receptor for host cell infectivity [ 17 ] .\n",
      "ARG1 PREDS: \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[92m[c]2019-nCoV\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91minfectivity\u001b[0m, \u001b[91mmay\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91m,\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]2\u001b[0m, \u001b[91muse\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91minfectivity\u001b[0m, \u001b[91muse\u001b[0m\n",
      "============================\n",
      "RESULT: The \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m virus utilizes \u001b[1m[\u001b[94mARG2 Angiotensin Converting Enzyme 2 ( ACE2 ) receptors ]\u001b[0m as its cell surface receptor , similar to the SARS 2002 - 3 virus .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91m3\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mvirus\u001b[0m, \u001b[91m-\u001b[0m, \u001b[91m2002\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]ACE2\u001b[0m, \u001b[94m[p]2\u001b[0m, \u001b[92m[c]Enzyme\u001b[0m, \u001b[92m[c]Angiotensin\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91msurface\u001b[0m, \u001b[94m[p]Converting\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m\n",
      "============================\n",
      "RESULT: Presumably , \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m infects cells through the S protein , which binds to \u001b[1m[\u001b[94mARG2 cell surface receptor-angiotensin-converting enzyme 2 ]\u001b[0m [ 4 ] .\n",
      "ARG1 PREDS: \u001b[91m2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mS\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91mthe\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mwhich\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91minfects\u001b[0m\n",
      "ARG2 PREDS: \u001b[94m[p]2\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[94m[p]cell\u001b[0m, \u001b[92m[c]surface\u001b[0m, \u001b[92m[c]surface\u001b[0m, \u001b[92m[c]surface\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[92m[c]receptor-angiotensin-converting\u001b[0m, \u001b[91mto\u001b[0m\n",
      "============================\n",
      "RESULT: \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m utilizes \u001b[1m[\u001b[94mARG2 ACE2 ]\u001b[0m as a receptor for entry into the host pneumocytes [ 13 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mutilizes\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mas\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mutilizes\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91mas\u001b[0m, \u001b[91m[\u001b[0m\n",
      "============================\n",
      "RESULT: Several studies also confirm that \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m also leverages \u001b[1m[\u001b[94mARG2 the ACE2 receptor ]\u001b[0m to gain entry into target cells ( 5 ) ( 6 ) ( 7 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91malso\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mstudies\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mentry\u001b[0m, \u001b[91mtarget\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91mcells\u001b[0m, \u001b[91minto\u001b[0m, \u001b[91malso\u001b[0m\n",
      "============================\n",
      "RESULT: The receptor-binding motif of \u001b[1m[\u001b[94mARG1 2019-nCoV ]\u001b[0m has undergone modification SARS-CoV and \u001b[1m[\u001b[94mARG1 2019-nCoV ]\u001b[0m enter the cell in the same waythrough binding \u001b[1m[\u001b[94mARG2 ACE2 ]\u001b[0m , which is present in lung and gastrointestinal epithelia [ 30 ] .\n",
      "ARG1 PREDS: \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[92m[c]2019-nCoV\u001b[0m, \u001b[91mof\u001b[0m, \u001b[92m[c]2019-nCoV\u001b[0m, \u001b[91mThe\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mThe\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91mbinding\u001b[0m, \u001b[91mof\u001b[0m, \u001b[91mlung\u001b[0m, \u001b[91mhas\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m[\u001b[0m\n",
      "============================\n",
      "RESULT: Similar to SARS , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m is believed to invade the host through \u001b[1m[\u001b[94mARG2 the cell entry receptor ACE2 ]\u001b[0m [ 4 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mis\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[91m[\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mcell\u001b[0m, \u001b[91m,\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]cell\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91mhost\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[92m[c]entry\u001b[0m, \u001b[91m[\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mis\u001b[0m\n",
      "============================\n",
      "RESULT: Similar to SARS-CoV , \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m exploits \u001b[1m[\u001b[94mARG2 angiotensin-converting enzyme 2 ( ACE2 ) ]\u001b[0m as a receptor to invade cells , notably type II alveolar epithelial cells .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91m,\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mexploits\u001b[0m, \u001b[91mreceptor\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[94m[p]2\u001b[0m, \u001b[91mexploits\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[94m[p](\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[91ma\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91malveolar\u001b[0m, \u001b[91mepithelial\u001b[0m\n",
      "============================\n",
      "RESULT: Both \u001b[1m[\u001b[94mARG1 SARS-CoV ]\u001b[0m and \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m bind to \u001b[1m[\u001b[94mARG2 the ACE2 receptor ]\u001b[0m through the Spike ( S ) protein ( Kuba et al. , 2005 ; Yan et al. , 2020 ) .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[92m[c]SARS-CoV\u001b[0m, \u001b[91mBoth\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mBoth\u001b[0m, \u001b[91m(\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mBoth\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[94m[p]the\u001b[0m, \u001b[91m(\u001b[0m, \u001b[91mto\u001b[0m, \u001b[91mand\u001b[0m, \u001b[91mbind\u001b[0m\n",
      "============================\n",
      "RESULT: Further extensive structural analysis strongly suggests that \u001b[1m[\u001b[94mARG1 SARS-CoV-2 ]\u001b[0m may use \u001b[1m[\u001b[94mARG2 host receptor angiotensin-converting enzyme 2 ( ACE2 ) ]\u001b[0m to enter the cells [ 42 ] , the same receptor facilitating SARS-CoV to infect the airway epithelium and alveolar type 2 ( AT2 ) pneumocytes , pulmonary cells that synthesize pulmonary surfactant [ 43 ] .\n",
      "ARG1 PREDS: \u001b[92m[c]SARS-CoV-2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mSARS-CoV\u001b[0m, \u001b[91mACE2\u001b[0m, \u001b[91m2\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mthat\u001b[0m, \u001b[91mextensive\u001b[0m, \u001b[91mAT2\u001b[0m, \u001b[91mFurther\u001b[0m\n",
      "ARG2 PREDS: \u001b[92m[c]host\u001b[0m, \u001b[92m[c]2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[92m[c]ACE2\u001b[0m, \u001b[92m[c]receptor\u001b[0m, \u001b[91mSARS-CoV-2\u001b[0m, \u001b[92m[c]enzyme\u001b[0m, \u001b[91muse\u001b[0m, \u001b[91mreceptor\u001b[0m, \u001b[91mextensive\u001b[0m\n",
      "============================\n",
      "============================\n"
     ]
    }
   ],
   "source": [
    "query2sent2gold = load_gold()\n",
    "good, bad = 0., 0.\n",
    "good2, bad2 =  0., 0.\n",
    "preds = []\n",
    "\n",
    "def is_correct(ind, start_and_end, relevant):\n",
    "    \n",
    "    is_in_phrase = False\n",
    "    is_relevant = False\n",
    "    \n",
    "    for (start, end) in start_and_end:\n",
    "        \n",
    "        if ind >= start and ind <= end:\n",
    "            \n",
    "            is_in_phrase = True\n",
    "            if ind in relevant:\n",
    "                is_relevant = True\n",
    "    \n",
    "    return is_in_phrase, is_relevant\n",
    "        \n",
    "        \n",
    "def print_nicely(sent, arg1_borders, arg2_borders):\n",
    "    \n",
    "    \n",
    "    def is_start(k, borders):\n",
    "        return len([(s,e) for (s,e) in borders if s == k]) != 0\n",
    "    def is_end(k, borders):\n",
    "        return len([(s,e) for (s,e) in borders if e == k]) != 0\n",
    "    \n",
    "    sent_lst = sent.split(\" \")\n",
    "    sent_new = []\n",
    "    for i,w in enumerate(sent_lst):\n",
    "        \n",
    "        if is_start(i,arg1_borders) or is_start(i,arg2_borders):\n",
    "            \n",
    "            type_arg = color.BLUE + \"ARG1\" if is_start(i,arg1_borders) else color.BLUE + \"ARG2\"\n",
    "            sent_new.append(color.BOLD + \"[\" + type_arg)\n",
    "            \n",
    "        sent_new.append(w)\n",
    "\n",
    "        if is_end(i,arg1_borders) or is_end(i,arg2_borders):\n",
    "            \n",
    "            #type_arg = color.BLUE + \"ARG1\" if is_end(i,arg1_borders) else \"ARG2\" + color.END\n",
    "            sent_new.append(\"]\" + color.END)\n",
    "            \n",
    "    return \" \".join(sent_new)\n",
    "    \n",
    "\n",
    "for query in query2arg2preds.keys():\n",
    "    \n",
    "    fname = \"results{}.txt\".format(query)\n",
    "    \n",
    "    for sent_ind in range(len(query2arg2preds[query][0])):\n",
    "        \n",
    "        if sent_ind >= len(query2sent2gold[query].keys()): break # only look at sentences we have annotation for\n",
    "        \n",
    "        for arg in range(2):\n",
    "            #if arg == 0: print(query2arg2preds[query][arg][sent_ind][\"sent\"])\n",
    "            d = query2arg2preds[query][arg][sent_ind]\n",
    "            mask_relevant =  np.array(d[\"pred_idx\"]) != -1\n",
    "            idx_relevant, sims_relevant = np.array(d[\"pred_idx\"])[mask_relevant], np.array(d[\"preds_sims\"])[mask_relevant]\n",
    "            word_pred = [d[\"sent\"].split(\" \")[j] for j in idx_relevant]\n",
    "            \n",
    "            arg_key = \"arg1\" if arg == 0 else \"arg2\"\n",
    "\n",
    "            if query2sent2gold[query][sent_ind][arg_key] == []: continue\n",
    "             \n",
    "            in_phrae_and_relevant = [is_correct(idx_relevant[k], query2sent2gold[query][sent_ind][arg_key], query2sent2gold[query][sent_ind][\"relevant\"]) for k in range(len(idx_relevant))]\n",
    "            in_phrase, relevant = list(zip(*in_phrae_and_relevant))\n",
    "            preds_annotated = []\n",
    "            \n",
    "            for pos, (k,w) in enumerate(zip(idx_relevant, word_pred)):\n",
    "                \n",
    "                #if \"Individuals with diabetes\" in d[\"sent\"]:\n",
    "                #    print(w,k, in_phrase[pos], relevant[pos])\n",
    "            \n",
    "                w_anno = color.RED + w + color.END \n",
    "                if in_phrase[pos] and relevant[pos]:\n",
    "\n",
    "                    w_anno = color.GREEN + \"[c]\"+w + color.END\n",
    "                elif in_phrase[pos] and not relevant[pos]:\n",
    "                    w_anno = color.BLUE + \"[p]\" + w + color.END\n",
    "                    \n",
    "                \n",
    "                preds_annotated.append(w_anno)         \n",
    "                           \n",
    "            #print(query, sent_ind)\n",
    "            if arg == 0: \n",
    "                print(\"RESULT:\", print_nicely(d[\"sent\"], query2sent2gold[query][sent_ind][\"arg1\"], query2sent2gold[query][sent_ind][\"arg2\"]))\n",
    "\n",
    "            print(\"ARG{} PREDS:\".format(arg+1), \", \".join(preds_annotated[:10]))\n",
    "            preds.append((word_pred, in_phrase, relevant))\n",
    "                             \n",
    "            if in_phrase[0]:\n",
    "                good2 += 1\n",
    "            else:\n",
    "                bad2 += 1\n",
    "                \n",
    "            for (start,end) in query2sent2gold[query][sent_ind][arg_key]:\n",
    "                if idx_relevant[0] >=  start and idx_relevant[0] <= end:\n",
    "                     good += 1\n",
    "                     break\n",
    "            else:\n",
    "                    bad += 1\n",
    "                    \"\"\" \n",
    "                    print(\"query:\", query)\n",
    "                    print(\"sent_ind:\", sent_ind)\n",
    "                    print(d[\"sent\"])\n",
    "                    print(\"preds:\", word_pred[:5])\n",
    "                    print(\"argument:\", arg_key)\n",
    "                    print(\"gold:\", query2sent2gold[query][sent_ind][arg_key])\n",
    "                    print(\"pred:\", idx_relevant[:5])\n",
    "                    print(\"======================\")\n",
    "                    \"\"\"\n",
    "        \n",
    "        print(\"============================\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "rank_pred_in_phrase = [in_p.index(True) for (words,in_p,is_correct) in preds]\n",
    "rank_pred_is_correct = [is_correct.index(True) if True in is_correct else 20 for (words,in_p,is_correct) in preds]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "%matplotlib inline\n",
    "\n",
    "plt.hist(rank_pred_in_phrase, density=True, bins=30)\n",
    "plt.title(\"Rank of first in-phrase prediction\")\n",
    "plt.xlabel(\"Rank\")\n",
    "plt.ylabel(\"Normalized Frequency\")\n",
    "plt.xticks(range(0,25,2))\n",
    "plt.show()\n",
    "\n",
    "\n",
    "plt.hist(rank_pred_is_correct, density=True, bins=30)\n",
    "plt.title(\"Rank of first in-phrase & relevant prediction\")\n",
    "plt.xlabel(\"Rank\")\n",
    "plt.ylabel(\"Normalized Frequency\")\n",
    "plt.xticks(range(0,25,2))\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
